CUMULATIVE
SUPPLEMENT 12
DECEMBER 2000



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2000

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Cumulative Supplement 12

December 2000

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 2000

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 20th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 20h Edition List will then be added to the "Discontinued Drug Product List" appearing in the 21st Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When

this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
GALDERMA LABS INC (GALDERMA)	GALDERMA LABORATORIES LP (GALDERMA LABS LP)
GLOBAL PHARMACEUTICAL CORP (GLOBAL PHARM)	IMPAX LABORATORIES INC (IMPAX LABS)
HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)	AVENTIS PHARMACEUTICALS INC (AVENTIS PHARMS)
RHONE POULENC RORER PHARMACEUTICALS INC (RHONE POULENCE RORER)	AVENTIS PHARMACEUTICALS PRODUCTS INC (AVENTIS PHARM PROD)
ROCHE GLOBAL DEVELOPMENT (ROCHE GLOBAL)	ROCHE GLOBAL A DIVISION OF SYNTEX (USA) LLC (ROCHE GLOBAL DEV)
SYNTEX (USA) INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX FP INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX LABORATORIES INC SUB SYNTEX CORP (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
SYNTEX USA INC (SYNTEX)	SYNTEX (USA) LLC (SYNTEX (USA) LLC)
TAP HOLDINGS INC (TAP HOLDINGS)	TAP PHARMACEUTICAL PRODUCTS INC (TAP PHARM)
ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)
ZENECA LTD (ZENECA)	ASTRAZENECA UK LTD (ASTRAZENECA UK)
ZENECA PHARMACEUTICALS DIV ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 20th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 20th annual edition of the 1999 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/20bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1999) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1999	JUN 2000	SEP 2000	DEC 2000
DRUG PRODUCTS LISTED	10045	10186	10332	10360
SINGLE SOURCE	2599 (25.9%)	2617 (25.7%)	2662 (25.8%)	2682 (25.9%)
MULTISOURCE	7335 (73.0%)	7458 (73.2%)	7560 (73.2%)	7568 (73.1%)
THERAPEUTICALLY EQUIVALENT	6986 (69.5%)	7132 (70.0%)	7238 (70.1%)	7257 (70.0%)
NOT THERAPEUTICALLY EQUIVALENT	349 (3.5%)	326 (3.2%)	322 (3.1%)	311 (3.0%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	0	11	7	2
NUMBER OF APPLICANTS	576	580	587	594

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
TRIZIVIR

	+	GLAXO WELLCOME	EQ 300MG BASE;150MG;300MG	N21205 001 NOV 14, 2000

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
PHRENILIN FORTE

AB	+	AMARIN PHARMS	650MG;50MG	N88831 001 JUN 19, 1985
AB	*	CARNRICK	650MG;50MG	N88831 001 JUN 19, 1985

TABLET; ORAL
PHRENILIN

AB	+	AMARIN PHARMS	325MG;50MG	N87811 001 JUN 19, 1985
AB	*	CARNRICK	325MG;50MG	N87811 001 JUN 19, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001
AA		CARNRICK	120MG/5ML;12MG/5ML	N86024 001

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4

AA		ROXANE	300MG;60MG	N84667 001
	@		300MG;60MG	N84667 001

ACETAMINOPHEN W/ CODEINE NO. 2

AA		ROXANE	300MG;15MG	N84659 001
	@		300MG;15MG	N84659 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BARR	500MG;2.5MG	N40307 001 JUL 26, 2000
AA			500MG;5MG	N40308 001 JUL 26, 2000

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BARR	500MG;7.5MG	N40307 002 JUL 26, 2000
AA			500MG;10MG	N40309 001 JUL 26, 2000
AA			650MG;7.5MG	N40307 003 JUL 26, 2000
AA			650MG;10MG	N40307 004 JUL 26, 2000
AA			750MG;7.5MG	N40308 002 JUL 26, 2000
AA		MALLINCKRODT	325MG;5MG	N40409 001 OCT 20, 2000
AA			325MG;7.5MG	N40405 001 SEP 08, 2000
AA			325MG;10MG	N40400 001 JUL 26, 2000
AA	+	UCB	325MG;7.5MG	N40248 001 APR 28, 2000
AA			325MG;10MG	N40248 002 APR 28, 2000
	*		325MG;7.5MG	N40248 001 APR 28, 2000
AA		VINTAGE PHARMS	325MG;10MG	N40355 001 MAY 31, 2000
AA			500MG;10MG	N40356 001 MAY 31, 2000
AA			660MG;10MG	N40358 001 MAY 31, 2000
AA		WATSON LABS	660MG;10MG	N40094 003 AUG 08, 2000

LORTAB

AA	+	UCB	325MG;5MG	N40099 001 JUN 25, 1997
	*		325MG;5MG	N40099 001 JUN 25, 1997

NORCO

AA	+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997
	*		325MG;10MG	N40148 001 FEB 14, 1997

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

> DLT >	AP	SCHWARZ PHARMA	0.005MG/VIAL	N20649 001 JUN 12, 1997
> DLT				
> ADD >		@	0.005MG/VIAL	N20649 001 JUN 12, 1997
> ADD >				
> ADD >		+	0.01MG/VIAL	N20649 005 JUL 30, 1998
> ADD >				
> ADD >		+	0.02MG/VIAL	N20649 006 JUL 30, 1998
> ADD >				
> ADD >		+	0.04MG/VIAL	N20649 007 JUL 30, 1998
> ADD >				

ALTRETAMINE

CAPSULE; ORAL
HEXALEN

*	MEDIMMUNE ONCOLOGY	50MG	N19926 001 DEC 26, 1990
+	MGI PHARMA	50MG	N19926 001 DEC 26, 1990

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL

AB	GENEVA PHARMS TECH	100MG	N71293 001 FEB 18, 1987
AB	INVAMED	100MG	N71293 001 FEB 18, 1987

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL

+	MEDIMMUNE ONCOLOGY	500MG/VIAL	N20221 001 DEC 08, 1995
*	US BIOSCIENCE	500MG/VIAL	N20221 001 DEC 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

AP	ASTRAZENECA	EQ 50MG BASE/ML	N63167 001 DEC 14, 1995
AP		EQ 250MG BASE/ML	N63169 001 DEC 14, 1995
@		EQ 50MG BASE/ML	N63167 001 DEC 14, 1995
@		EQ 250MG BASE/ML	N63169 001 DEC 14, 1995

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

	BAXTER HLTHCARE	15%	N20107 001 FEB 05, 1993
@		15%	N20107 001 FEB 05, 1993
	TROPHAMINE		
	B BRAUN	6%	N19018 001 JUL 20, 1984
+		6%	N19018 001 JUL 20, 1984
	TROPHAMINE 10%		
	B BRAUN	10%	N19018 003 SEP 07, 1988
+		10%	N19018 003 SEP 07, 1988

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

AB	GLOBAL PHARM	100MG	N84574 001
AB		200MG	N84576 001
@	IMPAX LABS	100MG	N84574 001
@		200MG	N84576 001

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL

+	EON	400MG	N75315 002 JUN 30, 2000

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

AB	MD PHARM	10MG	N85864 001
AB		25MG	N85935 001
AB		50MG	N85936 001
AB		75MG	N86337 001
AB		100MG	N86336 001
AB		150MG	N86335 001
	@ MEDEVA PHARMS CA	10MG	N85864 001
	@	25MG	N85935 001
	@	50MG	N85936 001
		75MG	N86337 001
	@	100MG	N86336 001
	@	150MG	N86335 001
AB	PUREPAC PHARM	10MG	N88075 001 SEP 16, 1983
AB		25MG	N88076 001 MAY 20, 1983
AB		50MG	N88077 001 SEP 16, 1983
AB		75MG	N88078 001 SEP 16, 1983
AB		100MG	N88079 001 SEP 16, 1983
	@	10MG	N88075 001 SEP 16, 1983
	@	25MG	N88076 001 MAY 20, 1983
	@	50MG	N88077 001 SEP 16, 1983
	@	75MG	N88078 001 SEP 16, 1983
	@	100MG	N88079 001 SEP 16, 1983
AB	ROXANE	10MG	N86002 001
AB		25MG	N85944 001
AB		50MG	N85945 001
AB		75MG	N86004 001
AB		100MG	N86003 001
	@	10MG	N86002 001
	@	25MG	N85944 001
	@	50MG	N85945 001
	@	75MG	N86004 001
	@	100MG	N86003 001

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB		MYLAN	10MG;2MG	N70336 001 NOV 10, 1988
AB	+		10MG;2MG	**N70336 001** NOV 10, 1988
AB			10MG;4MG	N71442 001 NOV 10, 1988
AB	+		10MG;4MG	**N71442 001** NOV 10, 1988
AB			25MG;2MG	N70337 001 NOV 10, 1988
AB	+		25MG;2MG	**N70337 001** NOV 10, 1988
AB			25MG;4MG	N70338 001 NOV 10, 1988
AB	+		25MG;4MG	**N70338 001** NOV 10, 1988
AB			50MG;4MG	N71443 001 NOV 10, 1988
AB	+		50MG;4MG	**N71443 001** NOV 10, 1988

AMOXAPINE

TABLET; ORAL
AMOXAPINE

AB		WATSON LABS	150MG	N72421 001 MAY 11, 1989
AB	+		150MG	**N72421 001** MAY 11, 1989
	ASENDIN			
AB		LEDERLE	25MG	N18021 001
AB			50MG	N18021 002
AB			100MG	N18021 003
AB	*		150MG	N18021 004
	@		25MG	N18021 001
	@		50MG	N18021 002
	@		100MG	N18021 003
	@		150MG	N18021 004

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL
AMOXICILLIN

AB		MYLAN	125MG/5ML	N62090 001

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

	AMOXICILLIN		
AB	MYLAN	250MG/5ML	N62090 002
	@	125MG/5ML	N62090 001
	@	250MG/5ML	N62090 002

TABLET; ORAL

	AMOXICILLIN		
AB	RANBAXY	500MG	N65059 001 NOV 24, 2000
AB		875MG	N65059 002 NOV 24, 2000
AB	TEVA	500MG	N65056 001 SEP 18, 2000
AB		875MG	N65056 002 SEP 18, 2000
	AMOXIL		
AB	SMITHKLINE BEECHAM	500MG	N50754 002 JUL 10, 1998
AB	+	875MG	N50754 001 JUL 10, 1998
		500MG	N50754 002 JUL 10, 1998
	*	875MG	N50754 001 JUL 10, 1998

TABLET, CHEWABLE; ORAL

	AMOXICILLIN		
AB	RANBAXY	200MG	N65060 001 NOV 29, 2000
AB		400MG	N65060 002 NOV 29, 2000
	AMOXIL		
AB	SMITHKLINE BEECHAM	200MG	N50761 001 APR 15, 1999
AB	+	400MG	N50761 002 APR 15, 1999
		200MG	N50761 001 APR 15, 1999
	*	400MG	N50761 002 APR 15, 1999

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

	AUGMENTIN '500'		
	* SMITHKLINE BEECHAM	500MG;EQ 125MG BASE	N50564 002 AUG 06, 1984
		500MG;EQ 125MG BASE	N50564 002 AUG 06, 1984

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 12.5		
SHIRE	3.125MG;3.125MG;3.125MG; 3.125MG	N11522 012 AUG 31, 2000
ADDERALL 15		
SHIRE	3.75MG;3.75MG;3.75MG; 3.75MG	N11522 013 AUG 31, 2000
ADDERALL 7.5		
+ SHIRE	1.875MG;1.875MG;1.875MG; 1.875MG	N11522 011 AUG 31, 2000

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	TOTACILLIN-N		
AP	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62727 001 DEC 19, 1986
AP		EQ 2GM BASE/VIAL	N62727 002 DEC 19, 1986
	@	EQ 1GM BASE/VIAL	N62727 001 DEC 19, 1986
	@	EQ 2GM BASE/VIAL	N62727 002 DEC 19, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE		
AB	MYLAN	EQ 250MG BASE	N61755 001
AB		EQ 500MG BASE	N61755 002
	@	EQ 250MG BASE	N61755 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
AMPICILLIN TRIHYDRATE
@ MYLAN EQ 500MG BASE N61755 002

POWDER FOR RECONSTITUTION; ORAL
TOTACILLIN
> DLT > AB SMITHKLINE BEECHAM EQ 125MG BASE/5ML N62223 001
> DLT > AB EQ 250MG BASE/5ML N62223 002
> ADD > @ EQ 125MG BASE/5ML N62223 001
> ADD > @ EQ 250MG BASE/5ML N62223 002

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN
ROBERTS LABS EQ 0.5MG BASE N20333 001
MAR 14, 1997
* EQ 1MG BASE N20333 002
MAR 14, 1997
SHIRE EQ 0.5MG BASE N20333 001
MAR 14, 1997
+ EQ 1MG BASE N20333 002
MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO
* WYETH AYERST 5,000 UNITS/0.5ML N20227 002
MAY 23, 1997
* 10,000 UNITS/0.5ML N20227 001
MAY 23, 1997
+ 5,000 UNITS/0.5ML N20227 002
MAY 23, 1997
+ 10,000 UNITS/0.5ML N20227 001
MAY 23, 1997

ARGATROBAN

INJECTABLE; INJECTION
ACOVA
+ TX BIOTECH 100MG/ML N20883 001
JUN 30, 2000

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
TRISENOX
+ CELL THERAP 1MG/ML N21248 001
SEP 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAINE
+ DEPROCO 4%;EQ 0.01MG BASE/ML N20971 001
APR 03, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT
* FRESENIUS KABI N/A,80MG/VIAL,N/A,0.02MG/VIAL,N/A,
0.001MG/VIAL;400 IU/10ML,N/A;N/A,
0.14MG/VIAL,N/A,17MG/VIAL,N/A,
5MG/VIAL;0.2MG/10ML,N/A;N/A,
1MG/VIAL,N/A,1.4MG/VIAL,N/A,
1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,
N/A,7 IU/10ML,N/A N20176 001
DEC 29, 1993

VITAPED
@ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,
0.001MG/VIAL;400 IU/10ML,N/A;N/A,
0.14MG/VIAL;N/A,17MG/VIAL;N/A,
5MG/VIAL;0.2MG/10ML,N/A;N/A,
1MG/VIAL;N/A,1.4MG/VIAL;N/A,
1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,
N/A;7 IU/10ML,N/A N20176 001
DEC 29, 1993

ASPIRIN; METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL AND ASPIRIN
AB MCNEIL 325MG;400MG N89193 001
FEB 12, 1986
@ 325MG;400MG N89193 001
FEB 12, 1986

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN (HALF-STRENGTH)

AA	ROXANE	325MG;2.25MG;0.19MG	N87742 001 JUN 04, 1982
	@	325MG;2.25MG;0.19MG	N87742 001 JUN 04, 1982

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENEVA PHARMS TECH	25MG	N74265 001 FEB 28, 1994
AB		50MG	N74265 002 FEB 28, 1994
AB		100MG	N74265 003 FEB 28, 1994
AB	INVAMED	25MG	N74265 001 FEB 28, 1994
AB		50MG	N74265 002 FEB 28, 1994
AB		100MG	N74265 003 FEB 28, 1994

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PFIZER IRELAND PHARM	EQ 40MG BASE	N20702 003 DEC 17, 1996
+		EQ 80MG BASE	N20702 004 APR 07, 2000
+	WARNER LAMBERT EXPOR	EQ 40MG BASE	N20702 003 DEC 17, 1996

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
MALARONE

+	GLAXO WELLCOME	250MG;100MG	N21078 001 JUL 14, 2000

MALARONE PEDIATRIC

+	GLAXO WELLCOME	62.5MG;25MG	N21078 002 JUL 14, 2000

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN

+	AMARIN PHARMS	0.025MG;1MG	N17744 002
+	CARNRICK	0.025MG;1MG	N17744 002

MOTOFEN HALF-STRENGTH

@	AMARIN PHARMS	0.025MG;0.5MG	N17744 001
@	CARNRICK	0.025MG;0.5MG	N17744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	ABLE	0.025MG;2.5MG	N40395 001 NOV 27, 2000
AA	PAR PHARM	0.025MG;2.5MG	N40357 001 MAY 02, 2000

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS

+	BAXTER PHARM PROD	0.14MG/ML;10MG/ML	N19677 001 NOV 06, 1991
+		0.14MG/ML;10MG/ML	N19678 001 NOV 06, 1991
+	OHMEDA	0.14MG/ML;10MG/ML	N19677 001 NOV 06, 1991
+		0.14MG/ML;10MG/ML	N19678 001 NOV 06, 1991

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIVAR

+	ASTA	0.05%	N21127 001 MAY 22, 2000

BALSALAZIDE DISODIUM

CAPSULE; ORAL
COLAZAL

+	SALIX	750MG	N20610 001 JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
QVAR 40
+ 3M 0.04MG/INH N20911 002 SEP 15, 2000

QVAR 80
+ 3M 0.08MG/INH N20911 001 SEP 15, 2000

> ADD > BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

> ADD > GEL; TOPICAL
> ADD > BENZACLIN
> ADD > + DERMIK LABS 5%;EQ 1% BASE N50756 001 DEC 21, 2000
> ADD >

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL
BENZAMYCIN PAK
+ DERMIK LABS 5%;3% N50769 001 NOV 27, 2000

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
AA GENEVA PHARMS TECH 0.5MG N72264 001 FEB 27, 1989
AA 1MG N72265 001 FEB 27, 1989
AA 2MG N72266 001 FEB 27, 1989
AA INVAMED 0.5MG N72264 001 FEB 27, 1989
AA 1MG N72265 001 FEB 27, 1989
AA 2MG N72266 001 FEB 27, 1989

> ADD > BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

> ADD > LOTION; TOPICAL
> ADD > LOTRISONE
> ADD > + SCHERING PLOUGH RES EQ 0.05% BASE;1% N20010 001 DEC 08, 2000
> ADD >

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
BETAXOLOL
AT AKORN EQ 0.5% BASE N75386 001 JUN 30, 2000
AT NOVEX EQ 0.5% BASE N75446 001 SEP 28, 2000

BETOPTIC
AT + ALCON EQ 0.5% BASE N19270 001 AUG 30, 1985
+ EQ 0.5% BASE N19270 001 AUG 30, 1985

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION
URECHOLINE
+ MERCK 5MG/ML N06536 001
@ 5MG/ML N06536 001

TABLET; ORAL
BETHANECHOL CHLORIDE
AA DANBURY PHARMA 10MG N84408 001
AA 25MG N84441 001
AA 50MG N87444 001
@ 10MG N84408 001
@ 25MG N84441 001
@ 50MG N87444 001
DUVOID
AA ROBERTS LABS 10MG N86262 001
AA 25MG N86263 001
AA 50MG N85882 003
@ 10MG N86262 001
@ 25MG N86263 001
@ 50MG N85882 003
MYOTONACHOL
AA GLENWOOD 5MG N84188 001
AA 10MG N84188 003
AA 25MG N84188 004

BETHANECHOL CHLORIDE

TABLET; ORAL

		MYOTONACHOL			
	@	GLENWOOD	5MG	N84188 001	
	@		10MG	N84188 003	
	@		25MG	N84188 004	
		URECHOLINE			
AA	*	MERCK	5MG	N06536 003	
AA	*		10MG	N06536 002	
AA	*		25MG	N06536 004	
AA	*		50MG	N06536 005	
	@		5MG	N06536 003	
	@		10MG	N06536 002	
	@		25MG	N06536 004	
	@		50MG	N06536 005	
	+	ODYSSEY PHARMS	5MG	N89095 001	
				DEC 19, 1985	
	+		10MG	N88440 001	
				MAY 29, 1984	
	+		25MG	N88441 001	
				MAY 29, 1984	> ADD >
	+		50MG	N89096 001	> ADD >
				DEC 19, 1985	> ADD >
AA	*	SIDMAK LABS NJ	5MG	N89095 001	> ADD >
				DEC 19, 1985	> ADD >
AA	*		10MG	N88440 001	> ADD >
				MAY 29, 1984	
AA	*		25MG	N88441 001	
				MAY 29, 1984	
AA	*		50MG	N89096 001	
				DEC 19, 1985	

BEXAROTENE

GEL; TOPICAL

		TARGRETIN			
	+	LIGAND	1%	N21056 001	
				JUN 28, 2000	> ADD >
					> ADD >
					> ADD >
					> ADD >
					> ADD >
					> ADD >
					> DLT >
					> DLT >
					> DLT >
					> DLT >

BISOPROLOL FUMARATE

TABLET; ORAL

		BISOPROLOL FUMARATE			
AB		EON	5MG	N75643 001	
				NOV 16, 2000	
		BISOPROLOL FUMARATE			
AB		EON	10MG	N75643 002	
				NOV 16, 2000	
		ZEBETA			
AB		LEDERLE	5MG	N19982 002	
				JUL 31, 1992	
AB	+		10MG	N19982 001	
				JUL 31, 1992	
			5MG	N19982 002	
				JUL 31, 1992	
	*		10MG	N19982 001	
				JUL 31, 1992	

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	APOTHECON	2.5MG;6.25MG	N75642 002	
			DEC 27, 2000	
AB		5MG;6.25MG	N75642 001	
			DEC 27, 2000	
AB		10MG;6.25MG	N75642 003	
			DEC 27, 2000	
AB	CHELSEA LABS	2.5MG;6.25MG	N75469 001	
			SEP 25, 2000	
AB		5MG;6.25MG	N75469 002	
			SEP 25, 2000	
AB		10MG;6.25MG	N75469 003	
			SEP 25, 2000	
AB	EON	2.5MG;6.25MG	N75579 001	
			SEP 25, 2000	
AB		5MG;6.25MG	N75579 002	
			SEP 25, 2000	
AB		10MG;6.25MG	N75579 003	
			SEP 25, 2000	
AB	GENEVA PHARMS TECH	2.5MG;6.25MG	N75527 001	
			SEP 25, 2000	
AB		5MG;6.25MG	N75527 003	
			SEP 25, 2000	
AB		10MG;6.25MG	N75527 002	
			SEP 25, 2000	
AB	INVAMED	2.5MG;6.25MG	N75527 001	
			SEP 25, 2000	
AB		5MG;6.25MG	N75527 003	
			SEP 25, 2000	

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

> DLT >	AB	INVAMED	10MG;6.25MG	N75527 002 SEP 25, 2000
> DLT	AB	MYLAN	2.5MG;6.25MG	N75768 001 SEP 25, 2000
	AB		5MG;6.25MG	N75768 002 SEP 25, 2000
	AB		10MG;6.25MG	N75768 003 SEP 25, 2000
	AB	PUREPAC PHARM	2.5MG;6.25MG	N75672 001 SEP 25, 2000
	AB		5MG;6.25MG	N75672 002 SEP 25, 2000
	AB		10MG;6.25MG	N75672 003 SEP 25, 2000
	AB	ZENITH GOLDLINE	2.5MG;6.25MG	N75632 001 SEP 27, 2000
	AB		5MG;6.25MG	N75632 002 SEP 27, 2000
	AB		10MG;6.25MG	N75632 003 SEP 27, 2000

ZIAC

	AB	LEDERLE	2.5MG;6.25MG	N20186 003 MAR 26, 1993
	AB		5MG;6.25MG	N20186 001 MAR 26, 1993
	AB	+	10MG;6.25MG	N20186 002 MAR 26, 1993
			2.5MG;6.25MG	N20186 003 MAR 26, 1993
			5MG;6.25MG	N20186 001 MAR 26, 1993
		*	10MG;6.25MG	N20186 002 MAR 26, 1993

> ADD > BIVALIRUDIN

> ADD > INJECTABLE; INTRAVENOUS
> ADD > ANGIOMAX
> ADD > + MEDS (TMC) 250MG/VIAL N20873 001 DEC 15, 2000
> ADD >

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN

AP	FAULDING	EQ 15 UNITS BASE/VIAL	N65031 001 MAR 10, 2000
AP		EQ 30 UNITS BASE/VIAL	N65031 002 MAR 10, 2000
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N65033 001 JUN 27, 2000
AP		EQ 30 UNITS BASE/VIAL	N65033 002 JUN 27, 2000

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

AP	ASTRAZENECA	50MG/ML	N71151 001 AUG 10, 1987
	@	50MG/ML	N71151 001 AUG 10, 1987

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DC

AA	* ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984
	@	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984

MYPHETANE DC

AA	NORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985
AA	+	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985

BUDESONIDE

SUSPENSION; INHALATION

PULMICORT RESPULES

ASTRAZENECA	0.25MG/2ML	N20929 001 AUG 08, 2000

BUDESONIDE

SUSPENSION; INHALATION
PULMICORT RESPULES

+	ASTRAZENECA	0.5MG/2ML	N20929 002 AUG 08, 2000
@		1MG/2ML	N20929 003 AUG 08, 2000

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB	EON	**75MG**	**N75613 002** OCT 10, 2000
AB		**100MG**	**N75613 001** OCT 10, 2000
AB	GENEVA PHARMS TECH	**75MG**	**N75584 001** FEB 07, 2000
AB		**100MG**	**N75584 002** FEB 07, 2000
AB	INVAMED	**75MG**	**N75584 001** FEB 07, 2000
AB		**100MG**	**N75584 002** FEB 07, 2000
AB	MYLAN	**75MG**	**N75491 001** APR 17, 2000
AB		**100MG**	**N75491 002** APR 17, 2000

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL
BUSPAR

> ADD >	BRISTOL MYERS SQUIBB	5MG	N21190 001 DEC 20, 2000
> ADD >		7.5MG	N21190 002 DEC 20, 2000
> ADD >		10MG	N21190 003 DEC 20, 2000
> ADD > +		15MG	N21190 004 DEC 20, 2000

TABLET; ORAL
BUSPAR

*	BRISTOL MYERS SQUIBB	15MG	N18731 003 APR 22, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR

@	BRISTOL MYERS SQUIBB	10MG	N18731 004 APR 22, 1996
		15MG	N18731 003 APR 22, 1996
+		30MG	N18731 004 APR 22, 1996

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARB

AA	ALPHARMA	30MG/5ML	N85873 001
@		30MG/5ML	N85873 001

BUTISOL SODIUM

AA *	WALLACE LABS	30MG/5ML	N85380 001
+		30MG/5ML	N85380 001

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	ABBOTT	**1MG/ML**	**N75559 001** MAR 20, 2000
AP		**2MG/ML**	**N75559 002** MAR 20, 2000

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
CAFERGOT

BR *	NOVARTIS	100MG;2MG	N09000 002
+		100MG;2MG	N09000 002

MIGERGOT

BR	G AND W LABS	100MG;2MG	N86557 001 OCT 04, 1983
@		100MG;2MG	N86557 001 OCT 04, 1983

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
+ ABBOTT 100MG/ML N21117 001
JAN 28, 2000

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
CARDIOPLEGIC IN PLASTIC CONTAINER
AT BAXTER HLTHCARE 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N75323 001
APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER
AT + ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001
FEB 26, 1982
* 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 > ADD >
FEB 26, 1982 > ADD >
> ADD >

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
* ABBOTT EQ 90MG CALCIUM/5ML N80001 001 > ADD >
@ EQ 90MG CALCIUM/5ML N80001 001 > ADD >
> DLT >
> DLT >

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ATACAND HCT
ASTRAZENECA 16MG;12.5MG N21093 001
SEP 05, 2000
+ 32MG;12.5MG N21093 002
SEP 05, 2000

CANDICIDIN

OINTMENT; VAGINAL
VANOBID
@ AVENTIS PHARMS 0.6MG/GM N61596 001
* HOECHST MARION RSSL 0.6MG/GM N61596 001

CANDICIDIN

TABLET; VAGINAL
VANOBID
@ AVENTIS PHARMS 3MG N61613 001
* HOECHST MARION RSSL 3MG N61613 001

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE
AB DANBURY PHARMA 50MG;25MG N74832 001
DEC 29, 1997
@ 50MG;25MG N74832 001
DEC 29, 1997

CARBAMAZEPINE

SUSPENSION; ORAL
CARBAMAZEPINE
AB TARO 100MG/5ML N75875 001
DEC 21, 2000

TEGRETOL
AB + NOVARTIS 100MG/5ML N18927 001
DEC 18, 1987
* 100MG/5ML N18927 001
DEC 18, 1987

TABLET, CHEWABLE; ORAL
CARBAMAZEPINE
AB TARO PHARM INDS 100MG N75687 001
OCT 24, 2000

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA
AB WATSON LABS 10MG;100MG N73381 001
SEP 28, 1993
AB 25MG;100MG N73382 001
SEP 28, 1993
AB 25MG;250MG N73383 001
SEP 28, 1993
@ 10MG;100MG N73381 001
SEP 28, 1993

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ WATSON LABS	25MG;100MG	N73382 001 SEP 28, 1993
	@	25MG;250MG	N73383 001 SEP 28, 1993

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB	MYLAN	25MG;100MG	N75091 002 APR 21, 2000

SINEMET CR

AB	DUPONT PHARMS	25MG;100MG	N19856 002 DEC 24, 1992
		25MG;100MG	N19856 002 DEC 24, 1992

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	COREPHARMA	350MG	N40397 001 SEP 21, 2000

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

	* AVENTIS	7.7MG	N20637 001 SEP 23, 1996
	+ GUILFORD PHARMS	7.7MG	N20637 001 SEP 23, 1996

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL

AT	ALCON	1%	N75476 001 JAN 03, 2000	> DLT >
AT	BAUSCH AND LOMB	1%	N75546 001 JAN 20, 2000	> DLT >

OCUPRESS

AT	+ CIBA	1%	N19972 001 MAY 23, 1990	> DLT >

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

	* CIBA	1%	N19972 001 MAY 23, 1990

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN AND DEXTROSE

	+ B BRAUN	EQ 500MG BASE/VIAL	N50779 001 JUL 27, 2000
	+	EQ 1GM BASE/VIAL	N50779 002 JUL 27, 2000

CEFAZOLIN SODIUM

AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002 AUG 14, 1998
AP		EQ 1GM BASE/VIAL	N64169 002 AUG 14, 1998

CEFDINIR

CAPSULE; ORAL
OMNICEF

	+ ABBOTT	300MG	N50739 001 DEC 04, 1997
	* PARKE DAVIS	300MG	N50739 001 DEC 04, 1997

POWDER FOR RECONSTITUTION; ORAL
OMNICEF

	+ ABBOTT	125MG/5ML	N50749 001 DEC 04, 1997
	* PARKE DAVIS	125MG/5ML	N50749 001 DEC 04, 1997

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION
ZEFAZONE

	* PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N50637 001 DEC 11, 1989
	*	EQ 2GM BASE/VIAL	N50637 002 DEC 11, 1989

CEFMETAZOLE SODIUM

> ADD >		INJECTABLE; INJECTION		
> ADD >		ZEFAZONE		
> ADD >	+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N50637 001
> ADD >				DEC 11, 1989
> ADD >	@		EQ 2GM BASE/VIAL	N50637 002
> ADD >				DEC 11, 1989
> DLT >		~~ZEFAZONE IN PLASTIC CONTAINER~~		
> DLT >		~~PHARMACIA AND UPJOHN~~	~~EQ 20MG BASE/ML~~	~~N50683 001~~
> DLT >				~~DEC 29, 1992~~
> DLT >			~~EQ 40MG BASE/ML~~	~~N50683 002~~
> DLT >				~~DEC 29, 1992~~
> ADD >	@		EQ 20MG BASE/ML	N50683 001
> ADD >				DEC 29, 1992
> ADD >	@		EQ 40MG BASE/ML	N50683 002
> ADD >				DEC 29, 1992

CEFOTAXIME SODIUM

		INJECTABLE; INJECTION		
		CEFOTAXIME		
AP		AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N64200 001**
				MAR 24, 2000
AP			**EQ 1GM BASE/VIAL**	**N64200 002**
				MAR 24, 2000
AP			**EQ 2GM BASE/VIAL**	**N64200 003**
				MAR 24, 2000
AP			**EQ 10GM BASE/VIAL**	**N64201 001**
				MAR 24, 2000
	+		EQ 20GM BASE/VIAL	N64201 002
				MAR 24, 2000
		CLAFORAN		
AP	+	AVENTIS PHARMS	**EQ 500MG BASE/VIAL**	**N50547 001**
AP	+		**EQ 1GM BASE/VIAL**	**N50547 002**
AP	+		**EQ 2GM BASE/VIAL**	**N50547 003**
AP	+		**EQ 10GM BASE/VIAL**	**N50547 004**
				DEC 29, 1983
	‡	~~HOECHST MARION RSSL~~	~~EQ 500MG BASE/VIAL~~	~~N50547 001~~
	‡		~~EQ 1GM BASE/VIAL~~	~~N50547 002~~
	‡		~~EQ 2GM BASE/VIAL~~	~~N50547 003~~
	‡		~~EQ 10GM BASE/VIAL~~	~~N50547 004~~
				~~DEC 29, 1983~~

CEFOXITIN SODIUM

		INJECTABLE; INJECTION		
		CEFOXITIN		
AP		AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N65012 001**
				JUL 03, 2000
AP			**EQ 2GM BASE/2VIAL**	**N65012 002**
				JUL 03, 2000
AP			**EQ 10GM BASE/VIAL**	**N65011 001**
				JUL 03, 2000
AP		ESI LEDERLE	**EQ 1GM BASE/VIAL**	**N65051 001**
				SEP 11, 2000
AP			**EQ 2GM BASE/VIAL**	**N65051 002**
				SEP 11, 2000
AP			**EQ 10GM BASE/VIAL**	**N65050 001**
				SEP 11, 2000
		MEFOXIN		
AP	+	MERCK	**EQ 1GM BASE/VIAL**	**N50517 001**
AP			**EQ 1GM BASE/VIAL**	**N62757 001**
				JAN 08, 1987
AP	+		**EQ 2GM BASE/VIAL**	**N50517 002**
AP			**EQ 2GM BASE/VIAL**	**N62757 002**
				JAN 08, 1987
AP	+		**EQ 10GM BASE/VIAL**	**N50517 003**
	‡		~~EQ 1GM BASE/VIAL~~	~~N50517 001~~
			~~EQ 1GM BASE/VIAL~~	~~N62757 001~~
				~~JAN 08, 1987~~
	‡		~~EQ 2GM BASE/VIAL~~	~~N50517 002~~
			~~EQ 2GM BASE/VIAL~~	~~N62757 002~~
				~~JAN 08, 1987~~
	‡		~~EQ 10GM BASE/VIAL~~	~~N50517 003~~

CEFTIBUTEN DIHYDRATE

		CAPSULE; ORAL		
		CEDAX		
	+	BIOVAIL	EQ 400MG BASE	N50685 002
				DEC 20, 1995
	‡	~~SCHERING PLOUGH~~	~~EQ 400MG BASE~~	~~N50685 002~~
				~~DEC 20, 1995~~
		POWDER FOR RECONSTITUTION; ORAL		
		CEDAX		
		BIOVAIL	EQ 90MG BASE/5ML	N50686 001
				DEC 20, 1995
	+		EQ 180MG BASE/5ML	N50686 002
				DEC 20, 1995

CEFTIBUTEN DIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
CEDAX

*	SCHERING PLOUGH	EQ 90MG BASE/5ML	N50686 001 DEC 20, 1995
*		EQ 180MG BASE/5ML	N50686 002 DEC 20, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993
+		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984
*	ROCHE	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
		EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
*		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
*		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
		EQ 1GM BASE/VIAL	N62654 002 APR 30, 1987
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

*	ROCHE	EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984
		EQ 2GM BASE/VIAL	N62654 003 APR 30, 1987
*		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

@	HLR	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
+		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987
+		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987
@	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987
*		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987
*		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

+	HLR	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996
*	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
*		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996

CEFUROXIME SODIUM

INJECTABLE; IM - IV
CEFUROXIME SODIUM

AB	MARSAM	**EQ 750MG BASE/VIAL**	**N64035 001** FEB 26, 1993

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	MARSAM	EQ 750MG BASE/VIAL	N64035 001 FEB 26, 1993

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62592 001 JAN 10, 1986

INJECTABLE; INTRAVENOUS
KEFUROX

AP	LILLY	EQ 750MG BASE/VIAL	N62592 001 JAN 10, 1986

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

AB	* LILLY	EQ 125MG BASE/5ML	N50406 001
AB	*	EQ 250MG BASE/5ML	N50406 002
AB		EQ 250MG BASE/5ML	N62117 003
AB	+	EQ 250MG BASE/5ML	N62117 003
	@	EQ 125MG BASE/5ML	N50406 001
	@	EQ 250MG BASE/5ML	N50406 002

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

	* BAYER	0.4MG	N20740 005 MAY 24, 1999
		0.4MG	N20740 005 MAY 24, 1999
	+	0.8MG	N20740 006 JUL 24, 2000

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE

	* ASTA	EQ 0.25MG BASE/ML	N21197 001 AUG 11, 2000
	*	EQ 3MG BASE/ML	N21197 002 AUG 11, 2000

CETRORELIX

INJECTABLE; INJECTION
CETROTIDE

	+ SERONO INC	EQ 0.25MG BASE/ML	N21197 001 AUG 11, 2000
	+	EQ 3MG BASE/ML	N21197 002 AUG 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC

	+ SNOWBRAND	EQ 30MG BASE	N20989 002 JAN 11, 2000

CHENODIOL

TABLET; ORAL
CHENIX

	@ AXCAN	250MG	N18513 002 JUL 28, 1983
	@ AXCAN SCANDIPHARM	250MG	N18513 002 JUL 28, 1983

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR

AT	PARKEDALE	0.5%	N61220 001
	@	0.5%	N61220 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	NOVEX	0.12%	N75561 001 NOV 14, 2000

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	GLOBAL PHARM	4MG	N80809 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
@ IMPAX LABS 4MG N80809 001

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
OVIDREL
+ SERONO 0.25MG/VIAL N21149 001
SEP 20, 2000

CICLOPIROX

CREAM; TOPICAL
LOPROX
+ AVENTIS PHARMS 0.77% N18748 001
DEC 30, 1982

LOTION; TOPICAL
LOPROX
+ AVENTIS PHARMS 0.77% N19824 001
DEC 30, 1988

CICLOPIROX OLAMINE

CREAM; TOPICAL
LOPROX
+ HOECHST MARION RSSL 1% N18748 001
DEC 30, 1982

LOTION; TOPICAL
LOPROX
+ HOECHST MARION RSSL 1% N19824 001
DEC 30, 1988

CIMETIDINE

TABLET; ORAL
CIMETIDINE
AB ROXANE 300MG N74361 001
DEC 23, 1994
AB 400MG N74361 002
DEC 23, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE
AB ROXANE 800MG N74371 001
DEC 23, 1994
@ 300MG N74361 001
DEC 23, 1994
@ 400MG N74361 002
DEC 23, 1994
@ 800MG N74371 001
DEC 23, 1994

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL
AA NOVEX EQ 300MG BASE/5ML N75560 001
MAR 15, 2000

CISAPRIDE MONOHYDRATE

SUSPENSION, ORAL
PROPULSID
+ JANSSEN EQ 1MG BASE/ML N20398 001
SEP 15, 1995
@ EQ 1MG BASE/ML N20398 001
SEP 15, 1995

TABLET; ORAL
PROPULSID
JANSSEN EQ 10MG BASE N20210 001
JUL 29, 1993
+ EQ 20MG BASE N20210 002
DEC 23, 1993
@ EQ 10MG BASE N20210 001
JUL 29, 1993
@ EQ 20MG BASE N20210 002
DEC 23, 1993

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP BEDFORD 1MG/ML N75036 001
NOV 07, 2000

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN		
AP	BEDFORD	**10MG/VIAL**	**N74713 001** NOV 14, 2000
AP		**50MG/VIAL**	**N74713 002** NOV 14, 2000
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N74814 001** MAY 16, 2000
AP	PHARMACHEMIE	**1MG/ML**	**N74656 001** MAY 16, 2000
	PLATINOL		
AP +	BRISTOL MYERS	**10MG/VIAL**	**N18057 001**
AP +		**50MG/VIAL**	**N18057 002**
*		10MG/VIAL	N18057 001
*		50MG/VIAL	N18057 002

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

	CELEXA		
	FOREST LABS	EQ 40MG BASE	N20822 003 JUL 17, 1998
*		EQ 60MG BASE	N20822 004 JUL 17, 1998
		EQ 10MG BASE	N20822 001 APR 27, 2000
+		EQ 40MG BASE	N20822 003 JUL 17, 1998
@		EQ 60MG BASE	N20822 004 JUL 17, 1998

CLADRIBINE

INJECTABLE; INJECTION

	CLADRIBINE		
AP	BEDFORD	**1MG/ML**	**N75405 001** FEB 28, 2000

CLARITHROMYCIN

TABLET; ORAL

	BIAXIN		
	ABBOTT	250MG	N50662 001 OCT 31, 1991

CLARITHROMYCIN

TABLET; ORAL

	BIAXIN		
+	ABBOTT	250MG	N50662 001 OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL

	BIAXIN XL		
+	ABBOTT	500MG	N50775 001 MAR 03, 2000

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE		
AA	NOVEX	**EQ 0.5MG BASE/5ML**	**N75703 001** NOV 27, 2000

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	CLEOCIN T		
AB +	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50615 001** JAN 07, 1987
*		EQ 1% BASE	N50615 001 JAN 07, 1987
	CLINDAMYCIN PHOSPHATE		
AB	ALTANA	**EQ 1% BASE**	**N64160 001** JAN 28, 2000
BT	TARGET RES	EQ 1% BASE	N50782 001 NOV 27, 2000

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE		
AP	ASTRAZENECA	**EQ 150MG BASE/ML**	N62928 001 FEB 13, 1989
@		EQ 150MG BASE/ML	N62928 001 FEB 13, 1989

SOLUTION; TOPICAL

	CLINDAMYCIN PHOSPHATE		
AT	CLAY PARK	**EQ 1% BASE**	**N65049 001** MAY 25, 2000

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL
OLUX FOAM

+	CONNETICS	0.05%	N21142 001 MAY 26, 2000

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB2	TARO	0.05%	N75633 001 MAY 17, 2000

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	ALTANA	0.05%	N75368 001 FEB 15, 2000

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

> ADD >	AT	THAMES	0.05%	N75363 001 DEC 29, 2000
> ADD >				

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

> ADD >	AB	GENEVA PHARMS TECH	25MG	N74953 001 JUN 25, 1997
> ADD >				
> ADD >	AB		50MG	N74953 002 JUN 25, 1997
> ADD >				
> ADD >	AB		75MG	N74953 003 JUN 25, 1997
> ADD >				
> DLT >	AB	INVAMED	25MG	N74953 001 JUN 25, 1997
> DLT >				
> DLT >	AB		50MG	N74953 002 JUN 25, 1997
> DLT >				
> DLT >	AB		75MG	N74953 003 JUN 25, 1997
> DLT >				

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

> ADD >	AB	GENEVA PHARMS TECH	2MG	N74925 003 SEP 30, 1997
> ADD				
> DLT >	AB	INVAMED	0.5MG	N74925 001 SEP 30, 1997
> DLT >				
> DLT >	AB		1MG	N74925 002 SEP 30, 1997
> DLT >				
> DLT >	AB		2MG	N74925 003 SEP 30, 1997
> DLT >				
	AB	TORPHARM	0.5MG	N75468 001 OCT 06, 2000
	AB		1MG	N75468 002 OCT 06, 2000
	AB		2MG	N75468 003 OCT 06, 2000

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	TARO	3.75MG	N75731 003 APR 27, 2000
AB		7.5MG	N75731 002 APR 27, 2000
AB		15MG	N75731 001 APR 27, 2000

CLOTRIMAZOLE

TABLET; VAGINAL
MYCELEX-G

+	BAYER	500MG	N19069 001 APR 19, 1985
@		500MG	N19069 001 APR 19, 1985

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM

AB +	APOTHECON	EQ 250MG BASE	N61452 001
AB +		EQ 500MG BASE	N61452 002
@		EQ 250MG BASE	N61452 001

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

> ADD >	AB	GENEVA PHARMS TECH	0.5MG	N74925 001 SEP 30, 1997
> ADD >				
> ADD >	AB		1MG	N74925 002 SEP 30, 1997
> ADD >				

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM
@ APOTHECON EQ 500MG BASE N61452 002
CLOXAPEN
AB SMITHKLINE BEECHAM EQ 500MG BASE N61806 002
AB + EQ 500MG BASE N61806 002

CLOZAPINE

TABLET; ORAL
CLOZAPINE
AB GENEVA PHARMS 25MG N74546 001 AUG 30, 1996
AB 100MG N74546 002 AUG 30, 1996
@ 25MG N74546 001 AUG 30, 1996
@ 100MG N74546 002 AUG 30, 1996

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL
WELCHOL
* GELTEX 375MG N21141 001 MAY 26, 2000
+ SANKYO 375MG N21141 001 MAY 26, 2000

TABLET; ORAL
WELCHOL
* GELTEX 625MG N21176 001 MAY 26, 2000
+ SANKYO 625MG N21176 001 MAY 26, 2000

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A
* JOHNSON RN 309MG/COPPER N18680 001 NOV 15, 1984
+ POPULATION COUNCIL 309MG/COPPER N18680 001 NOV 15, 1984

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE
BP GLOBAL PHARM 25MG N09458 001
@ IMPAX LABS 25MG N09458 001

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM
* MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

SOLUTION; INHALATION
CROMOLYN SODIUM
> ADD > AN BAUSCH AND LOMB 10MG/ML N75585 001 DEC 21, 2000
> ADD > AN STERIPAK 10MG/ML N75271 001 JAN 18, 2000
AN WARRICK PHARMS 10MG/ML N75437 001 APR 21, 2000

SOLUTION, CONCENTRATE; ORAL
GASTROCROM
+ MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN
@ AVENTIS PHARMS 1MG/ML N80564 001
AP HOECHST MARION RSSL 1MG/ML N80564 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB GENEVA PHARMS TECH 10MG N73683 001 FEB 26, 1993
AB INVAMED 10MG N73683 001 FEB 26, 1993

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HCL

AT	ALCON UNIVERSAL	1%	N89162 001 JAN 24, 1991
AT	STERIS	1%	N89162 001 JAN 24, 1991

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

AB	ABBOTT	25MG	N65003 001 MAY 12, 2000
AB		50MG	N65003 002 MAY 12, 2000
AB		100MG	N65003 003 MAY 12, 2000
		50MG	N65003 002 MAY 12, 2000
AB	EON	25MG	N65017 002 JAN 13, 2000
AB		100MG	N65017 001 JAN 13, 2000
> ADD > AB	SIDMAK LABS	25MG	N65044 002 DEC 20, 2000
> ADD > AB		100MG	N65044 001 DEC 20, 2000
	NEORAL		
AB	NOVARTIS	25MG	N50715 001 JUL 14, 1995
AB		50MG	N50715 003 JUL 14, 1995
AB +		100MG	N50715 002 JUL 14, 1995
BX		25MG	N50715 001 JUL 14, 1995
BX +		100MG	N50715 002 JUL 14, 1995
@		50MG	N50715 003 JUL 14, 1995

SOLUTION; ORAL
CYCLOSPORINE

AB	ABBOTT	100MG/ML	N65025 001 MAR 03, 2000

CYCLOSPORINE

SOLUTION; ORAL
CYCLOSPORINE

@	ABBOTT	100MG/ML	N65025 001 MAR 03, 2000
	NEORAL		
AB +	NOVARTIS	100MG/ML	N50716 001 JUL 14, 1995
+		100MG/ML	N50716 001 JUL 14, 1995
	SANGCYA		
AB	SANGSTAT MEDCL	100MG/ML	N64195 001 OCT 31, 1998
@		100MG/ML	N64195 001 OCT 31, 1998

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

AP	GENSIA SICOR PHARMS	500MG/VIAL	N75259 001 SEP 22, 2000

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INJECTION
SYNERCID

RHONE POULENC RORER	350MG/VIAL; EQ 150MG BASE/VIAL	N50747 001 SEP 21, 1999
	350MG/VIAL; EQ 150MG BASE/VIAL	N50748 001 SEP 21, 1999

INJECTABLE; IV(INFUSION)
SYNERCID

AVENTIS	350MG/VIAL;150MG/VIAL	N50748 001 SEP 21, 1999
+	420MG/VIAL;180MG/VIAL	N50748 002 AUG 24, 2000

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

+	GILEAD	EQ 2MG BASE/ML	N50704 002 APR 08, 1996
*	NEXSTAR	EQ 2MG BASE/ML	N50704 002 APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP	+	BEDFORD	**EQ 5MG BASE/ML**	**N50731 001** JAN 30, 1998
	*		EQ 5MG BASE/ML	N50731 001 JAN 30, 1998
AP		GENSIA SICOR PHARMS	**EQ 5MG BASE/ML**	**N65035 001** JAN 24, 2000
	+		EQ 50MG BASE/VIAL	N64212 002 MAY 03, 1999

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
DECLOMYCIN

	*	LEDERLE	150MG	N50262 001
	@		150MG	N50262 001

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP		ABBOTT	**0.004MG/ML**	**N75220 001** AUG 28, 2000
AP		BEDFORD	**0.004MG/ML**	**N74575 001** FEB 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

AP		BEDFORD	**0.004MG/ML**	**N74574 001** FEB 18, 2000

SPRAY, METERED; NASAL
STIMATE

	+	AVENTIS BEHRING	0.15MG/SPRAY	N20355 001 MAR 07, 1994

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

	*	CENTEON	0.15MG/SPRAY	N20355 001 MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
CYCLESSA

			> ADD >	
			> ADD >	
			> ADD >	
			> ADD >	
	+	ORGANON INC	0.1MG,0.125MG,0.15MG;0.025MG, 0.025MG,0.025MG	N21090 001 DEC 20, 2000

MIRCETTE

	*	ORGANON	0.15MG;0.02MG	N20713 001 APR 22, 1998
	+		0.15MG,N/A;0.02MG,0.01MG	N20713 001 APR 22, 1998

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

BP		GLOBAL PHARM	0.75MG	N85376 001
	@	IMPAX LABS	0.75MG	N85376 001

DEXONE 1.5

BP		SOLVAY	1.5MG	N84990 001
	@		1.5MG	N84990 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	ALCON UNIVERSAL	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62721 001** NOV 17, 1986
AT	STERIS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

> DLT >	AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N64055 001 OCT 30, 1995
> DLT >				
> DLT >				
> DLT >				
> ADD >		@	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N64055 001 OCT 30, 1995
> ADD >				
> ADD >				

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986
AT	STERIS	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986

DEZOCINE

INJECTABLE; INJECTION
DALGAN

*	ASTRAZENECA	5MG/ML	N19082 001 DEC 29, 1989
*		10MG/ML	N19082 002 DEC 29, 1989
*		15MG/ML	N19082 003 DEC 29, 1989
@		5MG/ML	N19082 001 DEC 29, 1989
@		10MG/ML	N19082 002 DEC 29, 1989
@		15MG/ML	N19082 003 DEC 29, 1989

DIAZEPAM

INJECTABLE; INJECTION
DIZAC

@	PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

INJECTABLE, INTRAVENOUS
DIZAC

*	PHARMACIA AND UPJOHN	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL
DIAZEPAM

AB	ROXANE	2MG	N70356 001 JUN 17, 1986
AB		5MG	N70357 001 JUN 17, 1986
AB		10MG	N70358 001 JUN 17, 1986
@		2MG	N70356 001 JUN 17, 1986
@		5MG	N70357 001 JUN 17, 1986
@		10MG	N70358 001 JUN 17, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL
DICLOFENAC POTASSIUM

AB	GENEVA PHARMS TECH	50MG	N75229 001 NOV 20, 1998
AB	INVAMED	50MG	N75229 001 NOV 20, 1998

DICLOFENAC SODIUM

GEL; TOPICAL
SOLARAZE

+	SKYEPHARMA	3%	N21005 001 OCT 16, 2000

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM †

AB	FALCON PHARMS	0.1%	N20809 001 MAY 04, 1998

† SEE SECTION 1.3 OF INTRODUCTION

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM
@ FALCON PHARMS 0.1% N20809 001 MAY 04, 1998

VOLTAREN
AB + CIBA 0.1% N20037 001 MAR 28, 1991
+ 0.1% N20037 001 MAR 28, 1991

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM
AB BIOVAIL 100MG N75492 001 FEB 11, 2000

VOLTAREN-XR
AB + NOVARTIS 100MG N20254 001 MAR 08, 1996
+ 100MG N20254 001 MAR 08, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL
VIDEX EC
+ BRISTOL MYERS SQUIBB 125MG N21183 001 OCT 31, 2000
+ 200MG N21183 002 OCT 31, 2000
+ 250MG N21183 003 OCT 31, 2000
+ 400MG N21183 004 OCT 31, 2000

DIENESTROL

SUPPOSITORY; VAGINAL
DV
@ AVENTIS PHARMS 0.7MG N83517 001
+ HOECHST MARION RSSL 0.7MG N83517 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL
AB MD PHARM 25MG N85544 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL
@ MEDEVA PHARMS CA 25MG N85544 001

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION
STILPHOSTROL
+ BAYER 250MG/5ML N10010 001
@ 250MG/5ML N10010 001

TABLET; ORAL
STILPHOSTROL
+ BAYER 50MG N10010 002
@ 50MG N10010 002

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE
AB TARO 0.05% N75508 001 APR 24, 2000

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL
AB3 BIOVAIL 120MG N20939 001 JAN 28, 2000
AB3 180MG N20939 002 JAN 28, 2000
AB3 240MG N20939 003 JAN 28, 2000
AB3 300MG N20939 004 JAN 28, 2000
AB2 TORPHARM 120MG N74943 003 DEC 19, 2000
AB2 180MG N74943 002 DEC 19, 2000
AB2 240MG N74943 001 AUG 06, 1998

DILTIAZEM XR
AB TORPHARM 240MG N74943 001 AUG 06, 1998

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N75004 001 FEB 16, 2000

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

*	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
*		EQ 180MG HCL	N20506 002 OCT 04, 1996
*		EQ 240MG HCL	N20506 003 OCT 04, 1996
+	MERCK	EQ 120MG HCL	N20506 001 OCT 04, 1996
+		EQ 180MG HCL	N20506 002 OCT 04, 1996
+		EQ 240MG HCL	N20506 003 OCT 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM

*	AVENTIS PHARMS	EQ 180MG HCL;5MG	N20507 001 OCT 04, 1996
+	MERCK	EQ 180MG HCL;5MG	N20507 001 OCT 04, 1996

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL
RIMSO-50

> DLT >		RES INDS	50%	N17788 001
> ADD >	+		50%	N17788 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	GLOBAL PHARM	25MG	N80807 001
AA	GLOBAL PHARM	50MG	N80807 002
	IMPAX LABS	25MG	N80807 001
	@	50MG	N80807 002

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	PUREPAC PHARM	75MG	N89427 001 JUL 12, 1990
	@	75MG	N89427 001 JUL 12, 1990

DISULFIRAM

TABLET; ORAL
ANTABUSE

BX	WYETH AYERST	250MG	N07883 003
BX	*	500MG	N07883 002
	@	250MG	N07883 003
	@	500MG	N07883 002

DISULFIRAM

BX	DANBURY PHARMA	500MG	N86890 001
BX	+	500MG	N86890 001

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

	+ ABBOTT	EQ 500MG VALPROIC ACID	N21168 001 AUG 04, 2000

DOXAZOSIN MESYLATE

TABLET; ORAL
CARDURA

AB	+ PFIZER	EQ 1MG BASE	N19668 001 NOV 02, 1990
AB		EQ 2MG BASE	N19668 002 NOV 02, 1990

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB	PFIZER	EQ 4MG BASE	N19668 003 NOV 02, 1990	> DLT >
AB		EQ 8MG BASE	N19668 004 NOV 02, 1990	> DLT >
*		EQ 1MG BASE	N19668 001 NOV 02, 1990	> DLT >
		EQ 2MG BASE	N19668 002 NOV 02, 1990	> DLT >
		EQ 4MG BASE	N19668 003 NOV 02, 1990	> DLT >
		EQ 8MG BASE	N19668 004 NOV 02, 1990	> DLT >

DOXAZOSIN MESYLATE

AB	CHELSEA LABS	EQ 1MG BASE	N75426 001 OCT 18, 2000	
AB		EQ 2MG BASE	N75426 002 OCT 18, 2000	
AB		EQ 4MG BASE	N75426 003 OCT 18, 2000	
AB		EQ 8MG BASE	N75426 004 OCT 18, 2000	
AB	EON	EQ 1MG BASE	N75646 001 OCT 18, 2000	
AB		EQ 2MG BASE	N75646 002 OCT 18, 2000	
AB		EQ 4MG BASE	N75646 003 OCT 18, 2000	
AB		EQ 8MG BASE	N75646 004 OCT 18, 2000	
AB	GENEVA PHARMS TECH	EQ 1MG BASE	N75432 001 OCT 18, 2000	> ADD > > ADD >
AB		EQ 2MG BASE	N75432 002 OCT 18, 2000	> ADD > > ADD >
AB		EQ 4MG BASE	N75432 003 OCT 18, 2000	> ADD > > ADD >
AB		EQ 8MG BASE	N75432 004 OCT 18, 2000	
AB	GENPHARM	EQ 1MG BASE	N75466 001 OCT 18, 2000	
AB		EQ 2MG BASE	N75466 002 OCT 18, 2000	
AB		EQ 4MG BASE	N75466 003 OCT 18, 2000	
AB		EQ 8MG BASE	N75466 004 OCT 18, 2000	

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	INVAMED	EQ 1MG BASE	N75432 001 OCT 18, 2000
AB		EQ 2MG BASE	N75432 002 OCT 18, 2000
AB		EQ 4MG BASE	N75432 003 OCT 18, 2000
AB	KV PHARM	EQ 1MG BASE	N75609 001 OCT 18, 2000
AB		EQ 2MG BASE	N75609 002 OCT 18, 2000
AB		EQ 4MG BASE	N75609 003 OCT 18, 2000
AB		EQ 8MG BASE	N75609 004 OCT 18, 2000
AB	MYLAN	EQ 1MG BASE	N75509 001 OCT 19, 2000
AB		EQ 2MG BASE	N75509 002 OCT 19, 2000
AB		EQ 4MG BASE	N75509 003 OCT 19, 2000
AB		EQ 8MG BASE	N75509 004 OCT 19, 2000
AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001 OCT 18, 2000
AB		EQ 2MG BASE	N75574 002 OCT 18, 2000
AB		EQ 4MG BASE	N75574 003 OCT 18, 2000
AB		EQ 8MG BASE	N75574 004 OCT 18, 2000
AB	TEVA	EQ 1MG BASE	N75536 001 OCT 18, 2000
AB		EQ 2MG BASE	N75536 002 OCT 18, 2000
AB		EQ 4MG BASE	N75536 003 OCT 18, 2000
AB		EQ 8MG BASE	N75536 004 OCT 18, 2000
AB	TORPHARM	EQ 1MG BASE	N75580 001 OCT 18, 2000
AB		EQ 2MG BASE	N75580 002 OCT 18, 2000
AB		EQ 4MG BASE	N75580 003 OCT 18, 2000

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

AB	TORPHARM	EQ 8MG BASE	N75580 004 OCT 18, 2000
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75453 001 OCT 18, 2000
AB		EQ 2MG BASE	N75453 002 OCT 18, 2000
AB		EQ 4MG BASE	N75453 003 OCT 18, 2000
AB		EQ 8MG BASE	N75453 004 OCT 18, 2000

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

+	BIOGLAN PHAR	5%	N20126 001 APR 01, 1994
*	MEDICIS	5%	N20126 001 APR 01, 1994

DOXERCALCIFEROL

INJECTABLE; INJECTION
HECTOROL

+	BONE CARE	2 UGM/ML	N21027 001 APR 06, 2000

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB	EON	EQ 50MG BASE	N65032 001 JUN 30, 2000
AB		EQ 100MG BASE	N65032 002 JUN 30, 2000
AB	HALSEY	EQ 50MG BASE	N65041 001 APR 28, 2000
AB		EQ 100MG BASE	N65041 002 APR 28, 2000
> ADD > AB	PAR PHARM	EQ 50MG BASE	N65055 001 DEC 01, 2000
> ADD >			

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB	PAR PHARM	EQ 100MG BASE	N65055 002 DEC 01, 2000
AB	RANBAXY	EQ 50MG BASE	N65053 001 NOV 22, 2000
AB		EQ 100MG BASE	N65053 002 NOV 22, 2000
	MONODOX		
AB	OCLASSEN	EQ 50MG BASE	N50641 002 FEB 10, 1992
AB +		EQ 100MG BASE	N50641 001 DEC 29, 1989
		EQ 50MG BASE	N50641 002 FEB 10, 1992
*		EQ 100MG BASE	N50641 001 DEC 29, 1989

TABLET; ORAL
DOXYCYCLINE

	PAR PHARM	EQ 50MG BASE	N65070 001 DEC 15, 2000
+		EQ 100MG BASE	N65070 002 DEC 15, 2000

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	ASTRAZENECA	2.5MG/ML	N72018 001 OCT 20, 1988
AP		2.5MG/ML	N72019 001 OCT 19, 1988
AP		2.5MG/ML	N72021 001 OCT 19, 1988
@		2.5MG/ML	N72018 001 OCT 20, 1988
@		2.5MG/ML	N72019 001 OCT 19, 1988
@		2.5MG/ML	N72021 001 OCT 19, 1988

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA
+ WESTWOOD SQUIBB CLTN 13.9% N21145 001
JUL 27, 2000

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	APOTHECON	2.5MG	N75583 001 AUG 22, 2000
AB		5MG	N75583 002 AUG 22, 2000
AB		10MG	N75583 003 AUG 22, 2000
AB		20MG	N75583 004 AUG 22, 2000
AB	CHELSEA LABS	2.5MG	N75501 001 AUG 22, 2000
AB		5MG	N75501 002 AUG 22, 2000
AB		10MG	N75501 003 AUG 22, 2000
AB		20MG	N75501 004 AUG 22, 2000
AB	EON	2.5MG	N75621 001 AUG 22, 2000
AB		5MG	N75621 002 AUG 22, 2000
AB		10MG	N75621 003 AUG 22, 2000
AB		20MG	N75621 004 AUG 22, 2000
AB	GENEVA PHARMS	2.5MG	N75048 001 AUG 22, 2000
AB		5MG	N75048 002 AUG 22, 2000
AB		10MG	N75048 003 AUG 22, 2000
AB		20MG	N75048 004 AUG 22, 2000
AB	GENPHARM	2.5MG	N75472 001 AUG 22, 2000
AB		5MG	N75472 002 AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB	GENPHARM	10MG	N75472 003 AUG 22, 2000
AB		20MG	N75472 004 AUG 22, 2000
AB	KRKA DD NOVO MESTO	2.5MG	N75370 001 AUG 22, 2000
AB		5MG	N75370 002 AUG 22, 2000
AB		10MG	N75369 001 AUG 22, 2000
AB		20MG	N75369 002 AUG 22, 2000
AB	LEK PHARM	2.5MG	N75496 001 AUG 22, 2000
AB		5MG	N75496 002 AUG 22, 2000
AB		10MG	N75459 001 AUG 22, 2000
AB		20MG	N75459 002 AUG 22, 2000
AB	MYLAN	2.5MG	N75480 001 AUG 22, 2000
AB		5MG	N75480 002 AUG 22, 2000
AB		10MG	N75480 003 AUG 22, 2000
AB		20MG	N75480 004 AUG 22, 2000
AB	RANBAXY	2.5MG	N75556 001 AUG 22, 2000
AB		5MG	N75556 002 AUG 22, 2000
AB		10MG	N75556 003 AUG 22, 2000
AB		20MG	N75556 004 AUG 22, 2000
AB	TEVA	2.5MG	N75479 001 AUG 22, 2000
AB		5MG	N75479 002 AUG 22, 2000
AB		10MG	N75479 003 AUG 22, 2000
AB		20MG	N75479 004 AUG 22, 2000

ENALAPRIL MALEATE

TABLET; ORAL

	ENALAPRIL MALEATE			
AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
AB		5MG	N75483 002	AUG 22, 2000
AB		10MG	N75483 003	AUG 22, 2000
AB		20MG	N75483 004	AUG 22, 2000
AB	ZENITH GOLDLINE	2.5MG	N75482 001	AUG 22, 2000
AB		5MG	N75482 002	AUG 22, 2000
AB		10MG	N75482 003	AUG 22, 2000
AB		20MG	N75482 004	AUG 22, 2000
	VASOTEC			
AB	MERCK	2.5MG	N18998 005	JUL 26, 1988
AB		5MG	N18998 001	DEC 24, 1985
AB		10MG	N18998 002	DEC 24, 1985
AB	+	20MG	N18998 003	DEC 24, 1985
		2.5MG	N18998 005	JUL 26, 1988
		5MG	N18998 001	DEC 24, 1985
		10MG	N18998 002	DEC 24, 1985
	*	20MG	N18998 003	DEC 24, 1985

ENALAPRILAT

INJECTABLE; INJECTION

	ENALAPRILAT			
AP	ABBOTT	1.25MG/ML	N75456 001	AUG 22, 2000
AP		1.25MG/ML	N75458 001	AUG 22, 2000
AP	BEDFORD	1.25MG/ML	N75634 001	AUG 22, 2000

ENALAPRILAT

INJECTABLE; INJECTION

	ENALAPRILAT			
AP	FAULDING	1.25MG/ML	N75571 001	AUG 22, 2000
AP	GENSIA SICOR PHARMS	1.25MG/ML	N75578 001	AUG 22, 2000
	VASOTEC			
AP	+ MERCK	1.25MG/ML	N19309 001	FEB 09, 1988
	*	1.25MG/ML	N19309 001	FEB 09, 1988

ENFLURANE

LIQUID; INHALATION

	ETHRANE			
AN	+ BAXTER PHARM PROD	99.9%	N17087 001	
AN	* OHMEDA	99.9%	N17087 001	

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

	ERGOMAR			
AA	LOTUS BIOCHEM	2MG	N87693 001	FEB 24, 1983
	+	2MG	N87693 001	FEB 24, 1983
	ERGOSTAT			
AA	PARKE DAVIS	2MG	N88337 001	JUN 08, 1984
	@	2MG	N88337 001	JUN 08, 1984
	WIGRETTES			
AA	* ORGANON	2MG	N86750 001	JUL 29, 1982
	@	2MG	N86750 001	JUL 29, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYTHROMYCIN			
AT	ALPHARMA	1.5%	N62328 001	APR 19, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYTHROMYCIN		
	@ ALPHARMA	1.5%	N62328 001 APR 19, 1982
	SANSAC		
AT	GALDERMA LABS	2%	N62522 001 JAN 24, 1985
AT	HEALTHPOINT	2%	N62522 001 JAN 24, 1985

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

	PEDIAMYCIN		
AB	ROSS LABS	EQ 200MG BASE/5ML	N62305 001
	@	EQ 200MG BASE/5ML	N62305 001

SUSPENSION/DROPS; ORAL

	PEDIAMYCIN		
	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002
	@	EQ 100MG BASE/2.5ML	N62305 002

TABLET, CHEWABLE; ORAL

	PEDIAMYCIN		
AB	ROSS LABS	EQ 200MG BASE	N62306 001
	@	EQ 200MG BASE	N62306 001

ESTRADIOL

CREAM; VAGINAL

	ESTRACE		
	+ BRISTOL MYERS SQUIBB	0.01%	N86069 001 JAN 31, 1984
	+ WARNER CHILCOTT	0.01%	N86069 001 JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA		
AB	+ BERLEX LABS	0.05MG/24HR	N20375 001 DEC 22, 1994
AB	+	0.1MG/24HR	N20375 002 DEC 22, 1994
BX	+	0.05MG/24HR	N20375 001 DEC 22, 1994

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA		
BX	+ BERLEX LABS	0.1MG/24HR	N20375 002 DEC 22, 1994
	ESTRADIOL		
BX	CYGNUS CA	0.05MG/24HR	N21048 001 SEP 20, 1999
BX		0.075MG/24HR	N21048 002 SEP 20, 1999
BX		0.1MG/24HR	N21048 003 SEP 20, 1999
	@ JOHNSON RW	0.05MG/24HR	N21048 001 SEP 20, 1999
	@	0.075MG/24HR	N21048 002 SEP 20, 1999
	@	0.1MG/24HR	N21048 003 SEP 20, 1999
AB	MYLAN TECHNOLOGIES	0.05MG/24HR	N75233 001 FEB 24, 2000
AB		0.1MG/24HR	N75182 001 FEB 24, 2000
	VIVELLE		
	+ NOVARTIS	0.025MG/24HR	N20323 005 AUG 16, 2000

TABLET; ORAL

	ESTRADIOL		
AB	APPLIED ANAL	0.5MG	N40138 001 JAN 30, 1998
AB		1MG	N40138 002 JAN 30, 1998
AB		2MG	N40138 003 JAN 30, 1998
AB	ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
AB		1MG	N40138 002 JAN 30, 1998
AB		2MG	N40138 003 JAN 30, 1998

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

	LUNELLE		
	+ PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N20874 001 OCT 05, 2000

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENESTIN

	* DURAMED	0.9MG	N20992 003 MAR 24, 1999
		0.9MG	N20992 003 MAR 24, 1999
	+	1.25MG	N20992 004 MAR 13, 2000

ESTROGENS, ESTERIFIED

TABLET; ORAL
ESTRATAB

BP	* SOLVAY	2.5MG	N83857 001
	@	2.5MG	N83857 001
	MENEST		
BP	MONARCH PHARMS	2.5MG	N84949 001
	+	2.5MG	N84949 001

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION
ETHAMOLIN

	* CYPROS	50MG/ML	N19357 001 DEC 22, 1988
	+ QUESTCOR PHARM	50MG/ML	N19357 001 DEC 22, 1988

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
TRIVORA-21

AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 001 DEC 18, 1997
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 001 DEC 18, 1997

TABLET; ORAL-28
TRIVORA-28

AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 002 DEC 18, 1997

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28
TRIVORA-28

AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 002 DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
MODICON 21

AB	JOHNSON RW	0.035MG;0.5MG	N17488 001
AB	+	0.035MG;0.5MG	N17488 001
	OVCON-35		
	* BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N18127 001
	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127 001
	OVCON-50		
	@ BRISTOL MYERS SQUIBB	0.05MG;1MG	N18128 001
	@ WARNER CHILCOTT	0.05MG;1MG	N18128 001

TABLET; ORAL-28

	OVCON-35		
	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N17716 001
	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001
	OVCON-50		
	BRISTOL MYERS SQUIBB	0.05MG;1MG	N17576 001
	WARNER CHILCOTT	0.05MG;1MG	N17576 001

ETHOSUXIMIDE

SYRUP; ORAL
ETHOSUXIMIDE

AA	PHARM ASSOC	250MG/5ML	N40253 001 NOV 22, 2000

ETODOLAC

CAPSULE; ORAL
ETODOLAC

		AB	GENEVA PHARMS TECH	200MG	N74942 001 SEP 30, 1997
> ADD >	> ADD >	AB		300MG	N74942 002 SEP 30, 1997
> ADD >	> ADD >	AB	INVAMED	200MG	N74942 001 SEP 30, 1997
> DLT >	> DLT >				

ETODOLAC

CAPSULE; ORAL
ETODOLAC

> DLT >	AB	INVAMED	300MG	N74942 002 SEP 30, 1997
> DLT	AB	TORPHARM	200MG	N75419 001 JUL 28, 2000
	AB		300MG	N75419 002 JUL 28, 2000

TABLET; ORAL
ETODOLAC

	AB	GENEVA PHARMS TECH	400MG	N74846 001 FEB 28, 1997
	AB	INVAMED	400MG	N74846 001 FEB 28, 1997
	AB	TARO PHARM INDS	500MG	N75074 002 APR 25, 2000

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

	AB	POINT HOLDINGS	400MG	N75696 001 JUL 31, 2000
	AB	TEVA	500MG	N75665 002 JUL 31, 2000
	AB		600MG	N75665 001 JUL 31, 2000
	AB	WHITNEY PHARMS	400MG	N75696 001 JUL 31, 2000

LODINE XL

	AB	+ WYETH AYERST	400MG	N20584 001 OCT 25, 1996
	AB	+	500MG	N20584 003 JAN 20, 1998
	AB	+	600MG	N20584 002 OCT 25, 1996
		*	400MG	N20584 001 OCT 25, 1996
		*	500MG	N20584 003 JAN 20, 1998
		*	600MG	N20584 002 OCT 25, 1996

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

	+ ABBOTT	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997
	* ELAN PHARMA	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

AB	WATSON LABS	EQ 200MG BASE	N72294 001 AUG 17, 1988
AB		EQ 300MG BASE	N72293 001 AUG 17, 1988
	@	EQ 200MG BASE	N72294 001 AUG 17, 1988
	@	EQ 300MG BASE	N72293 001 AUG 17, 1988

TABLET; ORAL
FENOPROFEN CALCIUM

AB	WATSON LABS	EQ 600MG BASE	N72165 001 AUG 17, 1988
	@	EQ 600MG BASE	N72165 001 AUG 17, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION
SUBLIMAZE PRESERVATIVE FREE

AP	+ AKORN MFG	EQ 0.05MG BASE/ML	N16619 001
AP	* JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
ALLEGRA

	AVENTIS PHARMS	30MG	N20872 001 FEB 25, 2000
		60MG	N20872 002 FEB 25, 2000
	+	180MG	N20872 004 FEB 25, 2000

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
AP BEDFORD 500MG/VIAL N75387 001 APR 16, 2000 > ADD > > ADD >

FUDR
AP + ROCHE 500MG/VIAL N16929 001
* 500MG/VIAL N16929 001

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
PFIZER 150MG N20322 001 JUN 30, 1994
150MG N19949 004 JUN 30, 1994

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON
+ HLR 0.1MG/ML N20073 001 DEC 20, 1991
* ROCHE 0.1MG/ML N20073 001 DEC 20, 1991

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUONID
AT ALLERGAN HERBERT 0.025% N87156 002 SEP 06, 1984
@ 0.025% N87156 002 SEP 06, 1984

OINTMENT; TOPICAL
FLUONID
AT ALLERGAN HERBERT 0.025% N87157 001 SEP 06, 1984
@ 0.025% N87157 001 SEP 06, 1984

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
> DLT > AT BAUSCH AND LOMB 0.01% N40059 001 DEC 20, 1993
> DLT >

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
@ BAUSCH AND LOMB 0.01% N40059 001 DEC 20, 1993

FLUOROURACIL

CREAM; TOPICAL
FLUOROURACIL
+ DERMIK LABS 0.5% N20985 001 OCT 27, 2000

INJECTABLE; INJECTION
FLUOROURACIL
AP BIGMAR 50MG/ML N40379 001 NOV 15, 2000
AP GENSIA SICOR PHARMS 50MG/ML N40333 001 JAN 27, 2000
AP 50MG/ML N40334 001 FEB 25, 2000

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
SARAFEM
LILLY EQ 10MG BASE N18936 007 JUL 06, 2000
+ EQ 20MG BASE N18936 008 JUL 06, 2000

FLURANDRENOLIDE

LOTION; TOPICAL
FLURANDRENOLIDE
AT ALPHARMA 0.05% N87203 001 APR 29, 1982
@ 0.05% N87203 001 APR 29, 1982

FLUTICASONE PROPIONATE

POWDER; INHALATION
FLOVENT DISKUS 100
+ GLAXO 0.1MG/INH N20833 002 SEP 29, 2000

FLOVENT DISKUS 250
+ GLAXO 0.25MG/INH N20833 003 SEP 29, 2000

FLOVENT DISKUS 50
+ GLAXO 0.05MG/INH N20833 001 SEP 29, 2000 > ADD >

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADVAIR DISKUS 100/50
+ GLAXO WELLCOME 0.1MG/INH; EQ 0.05MG BASE/INH N21077 001 AUG 24, 2000

ADVAIR DISKUS 250/50
+ GLAXO WELLCOME 0.25MG/INH; EQ 0.05MG BASE/INH N21077 002 AUG 24, 2000

ADVAIR DISKUS 500/50
+ GLAXO WELLCOME 0.5MG/INH; EQ 0.05MG BASE/INH N21077 003 AUG 24, 2000

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL
LESCOL XL
+ NOVARTIS 80MG N21192 001 OCT 06, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE
AB EON **25MG** **N75888 001** NOV 29, 2000
AB **50MG** **N75888 002** NOV 29, 2000
AB **100MG** **N75888 003** NOV 29, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE
AB MYLAN **25MG** **N75889 001** NOV 29, 2000
AB **50MG** **N75889 002** NOV 29, 2000
AB **100MG** **N75889 003** NOV 29, 2000
AB PUREPAC PHARM **25MG** **N75901 001** DEC 28, 2000
AB **50MG** **N75901 002** DEC 28, 2000
AB **100MG** **N75901 003** DEC 28, 2000

LUVOX
AB SOLVAY **25MG** **N20243 001** DEC 05, 1994
AB **50MG** **N20243 002** DEC 05, 1994
AB + **100MG** **N20243 003** DEC 05, 1994
~~25MG~~ ~~N20243 001 DEC 05, 1994~~
~~50MG~~ ~~N20243 002 DEC 05, 1994~~
~~+~~ ~~100MG~~ ~~N20243 003 DEC 05, 1994~~

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION
GONAL-F
SERONO 37.5 IU/VIAL N20378 003 MAY 25, 2000

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE
~~+ ROBERTS LABS~~ ~~50MG/15ML~~ ~~N11323 002~~
+ SHIRE 50MG/15ML N11323 002

TABLET; ORAL
FUROXONE
~~+ ROBERTS LABS~~ ~~100MG~~ ~~N11270 002~~

FURAZOLIDONE

TABLET; ORAL
FUROXONE
+ SHIRE 100MG N11270 002

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP ASTRAZENECA 10MG/ML N70095 001 SEP 09, 1985
AP 10MG/ML N70096 001 SEP 09, 1985
@ 10MG/ML N70095 001 SEP 09, 1985
@ 10MG/ML N70096 001 SEP 09, 1985

GABAPENTIN

SOLUTION; ORAL
NEURONTIN
* PARKE DAVIS 250MG/5ML N21129 001 MAR 02, 2000
@ 250MG/5ML N21129 001 MAR 02, 2000

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST
+ BERLEX LABS 469.01MG/ML N21037 001 MAR 10, 2000

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL
AB WATSON LABS 600MG N74156 001 OCT 24, 1994 > ADD >
@ 600MG N74156 001 OCT 24, 1994 > ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH AYERST 5MG/VIAL N21174 001 MAY 17, 2000

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GARAMYCIN
AP * SCHERING EQ 10MG BASE/ML N61739 001
@ EQ 10MG BASE/ML N61739 001
GENTAMICIN SULFATE
AP ELKINS SINN EQ 10MG BASE/ML N62251 002
AP + EQ 10MG BASE/ML N62251 002

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
AT ALCON UNIVERSAL EQ 0.3% BASE N62523 001 NOV 25, 1985
AT STERIS EQ 0.3% BASE N62523 001 NOV 25, 1985

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE
@ MD PHARM 500MG N85171 001
@ MEDEVA PHARMS CA 500MG N85171 001

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)
AB AVENTIS PHARMS 6MG N20055 003 MAR 08, 2000
AB GENEVA PHARMS TECH 1.5MG N75174 001 JUN 22, 1998
AB 3MG N75174 002 JUN 22, 1998
AB INVAMED 1.5MG N75174 001 JUN 22, 1998
AB 3MG N75174 002 JUN 22, 1998

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE

	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001 JUL 31, 2000
		2.5MG;500MG	N21178 002 JUL 31, 2000
+		5MG;500MG	N21178 003 JUL 31, 2000

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62818 001 OCT 11, 1988
	@	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62818 001 OCT 11, 1988

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

	GLAXO WELLCOME	EQ 200MG BASE	N20695 001 NOV 06, 1997
		EQ 400MG BASE	N20695 002 MAY 14, 1998
*		EQ 600MG BASE	N20695 003 MAY 14, 1998
	OTSUKA	EQ 200MG BASE	N20695 001 NOV 06, 1997
		EQ 400MG BASE	N20695 002 MAY 14, 1998
+		EQ 600MG BASE	N20695 003 MAY 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL
GRIFULVIN V

AB	J AND J	250MG	N60618 002
AB		500MG	N60618 003
		125MG	N60618 001

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL
GRIFULVIN V

	@ J AND J	125MG	N60618 001
	@	250MG	N60618 002
	@	500MG	N60618 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
GRIS-PEG

AB	ALLERGAN HERBERT	125MG	N50475 001
AB		250MG	N50475 002
AB	PEDINOL	125MG	N50475 001
AB		250MG	N50475 002

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	APOTEX	EQ 50MG BASE/ML	N75440 001 FEB 28, 2000
AO		EQ 100MG BASE/ML	N75440 002 FEB 28, 2000
AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001 FEB 09, 2000
AO		EQ 100MG BASE/ML	N75176 002 FEB 09, 2000

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SMITH AND NEPHEW	10 UNITS/ML	N87904 001 APR 20, 1983
AP		100 UNITS/ML	N87906 001 APR 20, 1983
	@	10 UNITS/ML	N87904 001 APR 20, 1983
	@	100 UNITS/ML	N87906 001 APR 20, 1983
	@ STERIS	100 UNITS/ML	N17064 001
	@	100 UNITS/ML	N17064 001
	HEPARIN SODIUM		
AP	STERIS	5,000 UNITS/ML	N17064 003

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM		
AP	STERIS	10,000 UNITS/ML	N17064 004
AP		20,000 UNITS/ML	N17064 005
AP		40,000 UNITS/ML	N17064 006
	@	5,000 UNITS/ML	N17064 003
	@	10,000 UNITS/ML	N17064 004
	@	20,000 UNITS/ML	N17064 005
	@	40,000 UNITS/ML	N17064 006

HEXACHLOROPHENE

AEROSOL; TOPICAL

	SEPTISOL		
	@ VESTAL LABS	0.23%	N17424 001

DISC; TOPICAL

	SEPTISOL		
*	VESTAL LABS	0.23%	N17424 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

	SUPPRELIN		
*	ROBERTS LABS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991
*		EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991
*		EQ 1MG BASE/ML	N19836 003 DEC 24, 1991
+	SHIRE	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991
+		EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991
+		EQ 1MG BASE/ML	N19836 003 DEC 24, 1991

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

> ADD >		**HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE**		
> ADD >	AA	AMIDE PHARM	1.5MG;5MG	N40295 001 DEC 01, 2000
> ADD >				

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL		
AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001 FEB 23, 2000
AP	+ LUITPOLD	20MG/ML	N40136 001 JUN 30, 1997
	*	20MG/ML	N40136 001 JUN 30, 1997

TABLET; ORAL

	HYDRALAZINE HCL		
AA	GLOBAL PHARM	25MG	N84922 001
	@ IMPAX LABS	25MG	N84922 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	APRESAZIDE		
AB	* NOVARTIS	100MG;50MG	N84811 001
	@	100MG;50MG	N84811 001
	HYDRA-ZIDE		
AB	PAR PHARM	100MG;50MG	N88961 001 OCT 21, 1985
	+	100MG;50MG	N88961 001 OCT 21, 1985

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE		
AB	MYLAN	12.5MG	N75640 001 JAN 28, 2000
	MICROZIDE		
AB	+ WATSON LABS	12.5MG	N20504 001 DEC 27, 1996
	*	12.5MG	N20504 001 DEC 27, 1996

TABLET; ORAL

	HYDROCHLOROTHIAZIDE		
AB	GLOBAL PHARM	100MG	N85098 001
	@ IMPAX LABS	100MG	N85098 001

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR

*	MERCK	12.5MG;50MG	N20387 001 APR 28, 1995
		12.5MG;50MG	N20387 001 APR 28, 1995
+		25MG;100MG	N20387 002 NOV 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	15MG;250MG	N71920 001 AUG 29, 1988
AB		25MG;250MG	N71921 001 AUG 29, 1988
AB		30MG;500MG	N71922 001 AUG 29, 1988
AB		50MG;500MG	N71923 001 AUG 29, 1988
	@	15MG;250MG	N71920 001 AUG 29, 1988
	@	25MG;250MG	N71921 001 AUG 29, 1988
	@	30MG;500MG	N71922 001 AUG 29, 1988
	@	50MG;500MG	N71923 001 AUG 29, 1988

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL
MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N21162 001 NOV 17, 2000
+		12.5MG;80MG	N21162 002 NOV 17, 2000

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
CODAMINE

AA	ALPHARMA	5MG/5ML;25MG/5ML	N75103 001 SEP 29, 2000

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
HYCOMINE

AA	+ ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001 AUG 17, 1990
	+	5MG/5ML;25MG/5ML	N19410 001 AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT	ZENITH GOLDLINE	1%	N85733 001
	@	1%	N85733 001

NOGENIC HC

AT	ZENITH GOLDLINE	1%	N87427 001 APR 04, 1988
	@	1%	N87427 001 APR 04, 1988

NUTRACORT

AT	GALDERMA LABS	0.5%	N80442 002
AT		1%	N80442 003
AT	HEALTHPOINT	1%	N80442 003
	@	0.5%	N80442 002

GEL; TOPICAL
NUTRACORT

	@ GALDERMA LABS	1%	N84698 001
	@ HEALTHPOINT	1%	N84698 001

PENECORT

*	ALLERGAN HERBERT	1%	N88215 001 JUN 06, 1984
	@	1%	N88215 001 JUN 06, 1984

LOTION; TOPICAL
HYDROCORTISONE

AT	ALTANA	2.5%	N40351 001 JUL 25, 2000

NUTRACORT

AT	GALDERMA LABS	0.5%	N80443 002
AT		1%	N80443 003
AT		2.5%	N87644 001 AUG 24, 1982
AT	HEALTHPOINT	1%	N80443 003
AT		2.5%	N87644 001 AUG 24, 1982

HYDROCORTISONE

LOTION; TOPICAL
NUTRACORT
@ HEALTHPOINT 0.5% N80443 002

OINTMENT; TOPICAL
HYDROCORTISONE
> ADD > **AT** THAMES **2.5%** **N40310 001**
> ADD > DEC 29, 2000

HYTONE
AT + DERMIK LABS **1%** **N80474 003**
AT + **2.5%** **N80474 004**
@ 1% N80474 003
@ 2.5% N80474 004

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N62874 001**
MAY 11, 1988
AT STERIS **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N62874 001**
MAY 11, 1988

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N62488 001**
NOV 06, 1985
AT STERIS **1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N62488 001**
NOV 06, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

DISC; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

DISC; TOPICAL
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N18795 001
JAN 07, 1983
@ YAMANOUCHI 0.1% N18795 001
JAN 07, 1983

LOCOID LIPOCREAM
YAMANOUCHI 0.1% N20769 001
SEP 08, 1997
+ 0.1% N20769 001
SEP 08, 1997

OINTMENT; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N19106 001
JUL 03, 1984
@ YAMANOUCHI 0.1% N19106 001
JUL 03, 1984

SOLUTION; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N19819 001
SEP 15, 1988
@ YAMANOUCHI 0.1% N19819 001
SEP 15, 1988

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE
AB CLAY PARK **0.2%** **N75666 001**
MAY 24, 2000

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE
AB GENEVA PHARMS TECH **200MG** **N40150 001**
JAN 27, 1996

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	INVAMED	200MG	N40150 001 JAN 27, 1996

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB	BARR	250MG	N75143 002 SEP 21, 2000
AB	DURAMED	250MG	N75020 002 JUN 26, 2000
AB +		250MG	N75020 002 JUN 26, 2000

TABLET; ORAL
HYDROXYUREA

+	BARR	1GM	N75734 001 AUG 29, 2000

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP	BEDFORD	EQ 5MG BASE/ML	N75513 001 MAY 09, 2000

AMRINONE LACTATE

AP	BAXTER PHARM PROD	EQ 5MG BASE/ML	N75542 001 MAY 10, 2000

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	WATSON LABS	25MG	N70529 001 OCT 18, 1985
AB		50MG	N70530 001 OCT 18, 1985
@		25MG	N70529 001 OCT 18, 1985
@		50MG	N70530 001 OCT 18, 1985

INSULIN ASPART RECOMBINANT

INJECTABLE; INJECTION
NOVOLOG

+	NOVO NORDISK	100 UNITS/ML	N20986 001 JUN 07, 2000

INSULIN GLARGINE

INJECTABLE; INJECTION
LANTUS

+	AVENTIS PHARMS	100 UNITS/ML	N21081 001 APR 20, 2000

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50

+	LILLY	50 UNITS/ML;50 UNITS/ML	N21018 001 DEC 22, 1999

HUMALOG MIX 75/25

+	LILLY	25 UNITS/ML;75 UNITS/ML	N21017 001 DEC 22, 1999

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50

*	LILLY	100 UNITS/ML	N21018 001 DEC 22, 1999

HUMALOG MIX 75/25

*	LILLY	100 UNITS/ML	N21017 001 DEC 22, 1999

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE

*	CYPROS	100MG/ML	N02282 001
+	QUESTCOR PHARM	100MG/ML	N02282 001

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-200		
AP	COOK IMAGING	41%	N74881 001 JUL 28, 2000
	IOPAMIDOL-250		
AP	COOK IMAGING	51%	N74881 002 JUL 28, 2000
	IOPAMIDOL-300		
AP	COOK IMAGING	61%	N74881 003 JUL 28, 2000
	IOPAMIDOL-370		
AP	COOK IMAGING	76%	N74881 004 JUL 28, 2000

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION

GLOFIL-125		
CYPROS	250-300 uCi/ML	N17279 001
QUESTCOR PHARM	250-300 uCi/ML	N17279 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

	IPRATROPIUM BROMIDE		
AN	STERIPAK	0.02%	N75313 001 FEB 07, 2000

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER		
+ LUITPOLD	EQ 20MG BASE/ML	N21135 001 NOV 06, 2000

ISOCARBOXAZID

TABLET; ORAL

MARPLAN		
+ OXFORD PHARM	10MG	N11961 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	BRONKOSOL		
AN	* SANOFI SYNTHELABO	1%	N12339 008
	@	1%	N12339 008
	ISOETHARINE HCL		
AN	* ASTRA PHARMS	0.125%	N89615 001 JUN 13, 1991
AN	*	0.167%	N89616 001 JUN 13, 1991
	*	0.062%	N89614 001 JUN 13, 1991
AN	* ASTRAZENECA	0.2%	N89617 001 JUN 13, 1991
AN	*	0.25%	N89618 001 JUN 13, 1991
	@	0.062%	N89614 001 JUN 13, 1991
	@	0.125%	N89615 001 JUN 13, 1991
	@	0.167%	N89616 001 JUN 13, 1991
	@	0.2%	N89617 001 JUN 13, 1991
	@	0.25%	N89618 001 JUN 13, 1991
AN	* INTL MEDICATION	0.1%	N86651 003
AN	*	0.167%	N86651 005
AN		0.2%	N86651 006
AN	*	0.25%	N86651 007
AN		1%	N86651 008
	*	0.077%	N86651 001
	*	0.08%	N86651 002
	*	0.143%	N86651 004
	@	0.077%	N86651 001
		0.08%	N86651 002
	@	0.1%	N86651 003
		0.143%	N86651 004
	@	0.167%	N86651 005
	@	0.2%	N86651 006
	@	0.25%	N86651 007
	@	1%	N86651 008
AN	ROXANE	0.1%	N87396 001
AN		0.125%	N87025 001
AN		0.167%	N88226 001 SEP 16, 1983
AN		0.2%	N87324 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

AN	ROXANE	0.25%	N88275 001 JUN 03, 1983
AN		1%	N86899 001
AN	+	1%	N86899 001
	@	0.1%	N87396 001
	@	0.125%	N87025 001
	+	0.167%	N88226 001 SEP 16, 1983
	+	0.2%	N87324 001
	@	0.25%	N88275 001 JUN 03, 1983

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER

	* SANOFI SYNTHELABO	0.34MG/INH	N12339 007
	@	0.34MG/INH	N12339 007

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN	RHODIA	99.9%	N74502 001 JUN 27, 1995
AN	RHONE POULENC	99.9%	N74502 001 JUN 27, 1995

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISUPREL

	* SANOFI SYNTHELABO	0.103MG/INH	N11178 001
	@	0.103MG/INH	N11178 001

SOLUTION; INHALATION
ISUPREL

	* SANOFI SYNTHELABO	0.5%	N06327 002
	*	1%	N06327 003
	@	0.5%	N06327 002
	@	1%	N06327 003

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL
ISORDIL

AB	* WYETH AYERST	40MG	N12882 001 JUL 29, 1988
	@	40MG	N12882 001 JUL 29, 1988

ISOSORBIDE DINITRATE

AB	INWOOD LABS	40MG	N40009 001 DEC 30, 1998
	+	40MG	N40009 001 DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISOSORBIDE MONONITRATE

AB	WEST WARD	20MG	N75361 001 OCT 05, 2000

TABLET, EXTENDED RELEASE; ORAL
IMDUR

AB	+ SCHERING	120MG	N20225 003 MAR 30, 1995
	*	120MG	N20225 003 MAR 30, 1995

ISOSORBIDE MONONITRATE

AB	DEXCEL LTD	60MG	N75522 001 APR 17, 2000
AB	KREMERS URBAN	30MG	N75155 002 JAN 13, 2000
AB		120MG	N75155 003 AUG 04, 2000
AB	KV PHARM	30MG	N75395 001 MAR 16, 2000
AB		60MG	N75395 002 MAR 16, 2000
AB		120MG	N75395 003 MAR 16, 2000
AB	ZENITH GOLDLINE	60MG	N75448 001 JUN 19, 2000

IVERMECTIN

TABLET; ORAL
STROMECTOL
MERCK 3MG N50742 002
OCT 08, 1998

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP PHARMAFAIR EQ 75MG BASE/2ML N62668 001
MAY 07, 1987
AP EQ 500MG BASE/2ML N62672 001
MAY 07, 1987
AP EQ 1GM BASE/3ML N62669 001
MAY 07, 1987
@ EQ 75MG BASE/2ML N62668 001
MAY 07, 1987
@ EQ 500MG BASE/2ML N62672 001
MAY 07, 1987
@ EQ 1GM BASE/3ML N62669 001
MAY 07, 1987

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE
AB TEVA 2% N75581 001
APR 25, 2000
NIZORAL
AB + MCNEIL CONS 2% N19084 001
DEC 31, 1985
* 2% N19084 001
DEC 31, 1985

SHAMPOO; TOPICAL
NIZORAL
* JANSSEN 2% N19927 001
AUG 31, 1990
+ MCNEIL CONS 2% N19927 001
AUG 31, 1990

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE
AP APOTHECON 15MG/ML N75348 001
NOV 28, 2000
AP 30MG/ML N75348 002
NOV 28, 2000

TABLET; ORAL
KETOROLAC TROMETHAMINE
AB ROXANE 10MG N74790 001
JUN 26, 1997
@ 10MG N74790 001
JUN 26, 1997

LACTULOSE

SOLUTION; ORAL
DUPHALAC
AA SOLVAY 10GM/15ML N72372 001
MAR 22, 1989
@ 10GM/15ML N72372 001
MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE
AP + ABBOTT EQ 10MG BASE/ML N40147 001
JUN 25, 1997
* EQ 10MG BASE/ML N40147 001
JUN 25, 1997
AP BEDFORD EQ 10MG BASE/ML N40347 001
APR 25, 2000
AP EQ 350MG BASE/VIAL N40335 001
APR 20, 2000
WELLCOVORIN
AP GLAXO WELLCOME EQ 100MG BASE/VIAL N89834 001
JAN 23, 1989
@ EQ 100MG BASE/VIAL N89834 001
JAN 23, 1989

TABLET; ORAL
LEUCOVORIN CALCIUM
> ADD > AB GENEVA PHARMS TECH EQ 15MG BASE N75327 001
> ADD > MAR 24, 1999

LEUCOVORIN CALCIUM

TABLET; ORAL
LEUCOVORIN CALCIUM

AB	*	IMMUNEX	EQ 15MG BASE	N71104 001 MAR 04, 1987
AB			EQ 15MG BASE	N71104 001 MAR 04, 1987
> DLT > AB		INVAMED	EQ 15MG BASE	N75327 001 MAR 24, 1999
> DLT > AB		ROXANE	EQ 25MG BASE	N72736 001 FEB 22, 1993
AB	+		EQ 25MG BASE	N72736 001 FEB 22, 1993

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
VIADUR

+	ALZA	EQ 65MG BASE	N21088 001 MAR 03, 2000

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	GENSIA SICOR PHARMS	1MG/0.2ML	N75471 001 OCT 25, 2000

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON

+	ALCON	EQ 0.5% BASE	N21114 001 FEB 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
LEVOBUNOLOL HCL

AT	NOVEX	0.25%	N75473 001 AUG 03, 2000
AT		0.5%	N75475 001 AUG 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE

	PURDUE PHARMA	EQ 2.5MG BASE/ML	N20997 001 AUG 05, 1999
		EQ 5MG BASE/ML	N20997 002 AUG 05, 1999
*		EQ 7.5MG BASE/ML	N20997 003 AUG 05, 1999
	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001 AUG 05, 1999
		EQ 5MG BASE/ML	N20997 002 AUG 05, 1999
+		EQ 7.5MG BASE/ML	N20997 003 AUG 05, 1999

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
QUIXIN

+	SANTEN	0.5%	N21199 001 AUG 18, 2000

TABLET; ORAL
LEVAQUIN

*	JOHNSON RW	500MG	N20634 002 DEC 20, 1996
		500MG	N20634 002 DEC 20, 1996
+		750MG	N20634 003 SEP 08, 2000

LEVONORGESTREL

> ADD > INTRAUTERINE DEVICE; INTRAUTERINE
> ADD > MIRENA
> ADD > + BERLEX LABS 52MG N21225 001
> ADD > DEC 08, 2000

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

AB	+ ICN	2MG	N08720 001 DEC 19, 1991

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

*	ICN	2MG	N08720 001 DEC 19, 1991

LEVORPHANOL TARTRATE

AB	ROXANE	**2MG**	**N74278 001** MAR 31, 2000

LEVOTHYROXINE SODIUM

TABLET; ORAL
UNITHROID

	STEVENS J	0.025MG	N21210 001 AUG 21, 2000
		0.05MG	N21210 002 AUG 21, 2000
		0.075MG	N21210 003 AUG 21, 2000
		0.088MG	N21210 004 AUG 21, 2000
		0.1MG	N21210 005 AUG 21, 2000
		0.112MG	N21210 006 AUG 21, 2000
		0.125MG	N21210 007 AUG 21, 2000
		0.15MG	N21210 008 AUG 21, 2000
		0.175MG	N21210 009 AUG 21, 2000
		0.2MG	N21210 010 AUG 21, 2000
+		0.3MG	N21210 011 AUG 21, 2000

LINEZOLID

GRANULE, FOR RECONSTITUTION; ORAL
ZYVOX

+	PHARMACIA AND UPJOHN	100MG/5ML	N21132 001 APR 18, 2000

INJECTABLE; INJECTION
ZYVOX

+	PHARMACIA AND UPJOHN	200MG/100ML	N21131 001 APR 18, 2000

LINEZOLID

TABLET; ORAL
ZYVOX

	PHARMACIA AND UPJOHN	400MG	N21130 001 APR 18, 2000
+		600MG	N21130 002 APR 18, 2000

LOPINAVIR; RITONAVIR

CAPSULE; ORAL
KALETRA

+	ABBOTT	133.3MG;33.3MG	N21226 001 SEP 15, 2000

SOLUTION; ORAL
KALETRA

+	ABBOTT	80MG/ML;20MG/ML	N21251 001 SEP 15, 2000

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP	MOVA	**2MG/ML**	**N74793 001** MAR 16, 2000
AP		**4MG/ML**	**N74793 002** MAR 16, 2000

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

AP	ABBOTT	**500MG/ML**	**N75151 001** APR 25, 2000
AP +	AM PHARM PARTNERS	**500MG/ML**	**N19316 001** SEP 08, 1986
*		500MG/ML	N19316 001 SEP 08, 1986

MASOPROCOL

CREAM; TOPICAL
ACTINEX

> DLT >	*	SCHWARZ PHARMA	10%	N19940 001
> DLT >				SEP 04, 1992
> ADD >	+	UNIV AZ CANCER CTR	10%	N19940 001
> ADD >				SEP 04, 1992

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
AMEN

BP	AMARIN PHARMS	10MG	N83242 001
BP	CARNRICK	10MG	N83242 001
	CURRETAB		
BP	SOLVAY	10MG	N85686 001
	@	10MG	N85686 001

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001
			FEB 27, 1998
AB	**TEVA**	**40MG**	**N74745 001**
			FEB 27, 1998

MELOXICAM

TABLET; ORAL
MOBIC

+	BOEHRINGER INGELHEIM	7.5MG	N20938 001
			APR 13, 2000

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
MENOTROPINS

@	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001
			JAN 30, 1997
@		150 IU/VIAL;150 IU/VIAL	N73599 001
			JAN 30, 1997
	REPRONEX		
AB	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001
			JAN 30, 1997

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
REPRONEX

AB	FERRING	150 IU/VIAL;150 IU/VIAL	N73599 001
			JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	MALLINCKRODT	**50MG**	**N40352 001**
			JUN 13, 2000
AA		**100MG**	**N40352 002**
			JUN 13, 2000

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE

*	WYETH AYERST	EQ 30MG BASE/ML	N08248 001
@		EQ 30MG BASE/ML	N08248 001

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	LANNETT	200MG	N14882 002
AA		400MG	N14882 001
@		200MG	N14882 002
@		400MG	N14882 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

*	ROBERTS LABS	250MG	N20049 001
			MAY 10, 1993
+	SHIRE	250MG	N20049 001
			MAY 10, 1993

SUPPOSITORY; RECTAL
ROWASA

*	SOLVAY	500MG	N19919 001
			DEC 18, 1990

MESALAMINE

SUPPOSITORY; RECTAL
ROWASA
@ SOLVAY 500MG N19919 001
DEC 18, 1990

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL
@ SEARLE 0.1MG;2MG N13625 004
@ WATSON LABS 0.1MG;2MG N13625 004

TABLET; ORAL-21
NORINYL 1+50 21-DAY
AB SEARLE 0.05MG;1MG N13625 002
AB WATSON LABS 0.05MG;1MG N13625 002

METAPROTERENOL SULFATE

SOLUTION; INHALATION
ALUPENT
AN * BOEHRINGER INGELHEIM 5% N17659 001
+ 5% N17659 001
METAPROTERENOL SULFATE
AN ASTRA PHARMS 0.4% N71275 001
JUL 27, 1988
AN 0.6% N71018 001
JUL 27, 1988
@ ASTRAZENECA 0.4% N71275 001
JUL 27, 1988
@ 0.6% N71018 001
JUL 27, 1988
PROMETA
AN MURO 5% N73340 001
MAR 30, 1992
@ 5% N73340 001
MAR 30, 1992

SYRUP; ORAL
METAPROTERENOL SULFATE
AA NOVEX 10MG/5ML N75235 001
JAN 27, 2000
PROMETA
AA MURO 10MG/5ML N72023 001
SEP 15, 1988

METAPROTERENOL SULFATE

SYRUP; ORAL
PROMETA
@ MURO 10MG/5ML N72023 001
SEP 15, 1988

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
GLUCOPHAGE XR
+ BRISTOL MYERS SQUIBB 500MG N21202 001
OCT 13, 2000

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE
* ROBERTS LABS 50MG N07390 001
+ SHIRE 50MG N07390 001

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN
* APOTHECON EQ 900MG BASE/VIAL N61449 001
* EQ 3.6GM BASE/VIAL N61449 002
* EQ 5.4GM BASE/VIAL N61449 003
@ EQ 900MG BASE/VIAL N61449 001
@ EQ 3.6GM BASE/VIAL N61449 002
@ EQ 5.4GM BASE/VIAL N61449 003

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE
AB APPLIED ANAL 5MG N40320 001
MAR 31, 2000
AB 10MG N40320 002
MAR 31, 2000
AB GENPHARM 5MG N40350 001
MAR 29, 2000
AB 10MG N40350 002
MAR 29, 2000

METHIMAZOLE

TABLET; ORAL

		METHIMAZOLE		
AB		JONES PHARMA	5MG	N40320 001 MAR 31, 2000
AB			10MG	N40320 002 MAR 31, 2000
		TAPAZOLE		
AB		LILLY	5MG	N07517 002
AB	+		10MG	N07517 004
	*		5MG	N07517 002
	*		10MG	N07517 004

METHOXYFLURANE

LIQUID; INHALATION

		PENTHRANE	
	*	ABBOTT	99.9% N13056 001
	@		99.9% N13056 001

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

		PAMINE		
> ADD >	AA	+ BRADLEY PHARMS	2.5MG	N08848 001
> DLT >	AA	* KENWOOD LABS	2.5MG	N08848 001

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		CONCERTA		
	+	ALZA	18MG	N21121 001 AUG 01, 2000
	+		36MG	N21121 002 AUG 01, 2000
> ADD >	+		54MG	N21121 003 DEC 08, 2000
> ADD >				
		METADATE ER		
AB	+	MEDEVA	10MG	N40306 001 OCT 20, 1999
	*		10MG	N40306 001 OCT 20, 1999
		METHYLIN ER		
AB		MALLINCKRODT	10MG	N75629 001 MAY 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		METHYLIN ER	
AB		MALLINCKRODT	20MG N75629 002 MAY 09, 2000

METHYLPREDNISOLONE

TABLET; ORAL

		METHYLPREDNISOLONE		
> ADD >	AB	GENEVA PHARMS TECH	4MG	N40194 001 OCT 31, 1997
> ADD >				
> DLT >	AB	INVAMED	4MG	N40194 001 OCT 31, 1997
> DLT >				

METHYLTESTOSTERONE

TABLET; ORAL

		ORETON METHYL	
BP		SCHERING	10MG N03158 001
BP			25MG N03158 002
	@		10MG N03158 001
	@		25MG N03158 002

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

		METOCLOPRAMIDE HCL	
AB		WATSON LABS	EQ 10MG BASE N70645 001 MAY 11, 1987
	@		EQ 10MG BASE N70645 001 MAY 11, 1987

METOPROLOL TARTRATE

TABLET; ORAL

		LOPRESSOR		
AB	*	NOVARTIS	50MG	N17963 001
AB			50MG	N17963 001

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

*	ADVANCED CARE PRODS	1.2GM,2%	N20968 001 JUN 30, 1999
+	PERSONAL PRODS	1.2GM,2%	N20968 001 JUN 30, 1999

TAMPON; VAGINAL
MONISTAT 5

@	ADVANCED CARE PRODS	100MG	N18592 001 OCT 27, 1989
@	PERSONAL PRODS	100MG	N18592 001 OCT 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	ABBOTT	EQ 1MG BASE/ML	N75293 001 JUN 20, 2000
AP		EQ 1MG BASE/ML	N75409 002 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75293 002 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75409 001 JUN 20, 2000
AP	AESGEN	EQ 1MG BASE/ML	N75154 002 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75154 001 JUN 20, 2000
AP	APOTEX	EQ 1MG BASE/ML	N75637 001 OCT 31, 2000
AP		EQ 5MG BASE/ML	N75637 002 OCT 31, 2000
AP	APOTHECON	EQ 1MG BASE/ML	N75620 001 NOV 01, 2000
AP		EQ 5MG BASE/ML	N75620 002 NOV 01, 2000
AP		EQ 5MG BASE/ML	N75641 001 OCT 19, 2000
AP	ASTRAZENECA	EQ 5MG BASE/ML	N75263 001 JUN 26, 2000
AP	BAXTER PHARM PROD	EQ 1MG BASE/ML	N75324 001 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75324 002 JUN 20, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	BEDFORD	EQ 1MG BASE/ML	N75247 002 JUN 23, 2000
AP		EQ 5MG BASE/ML	N75247 001 JUN 23, 2000
AP		EQ 5MG BASE/ML	N75249 001 JUN 23, 2000
AP	BEN VENUE	EQ 1MG BASE/ML	N75421 002 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75421 001 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75455 001 JUN 20, 2000
AP	ESI LEDERLE	EQ 1MG BASE/ML	N75243 001 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75243 002 JUN 20, 2000
AP	FAULDING	EQ 1MG BASE/ML	N75396 001 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75396 002 JUN 20, 2000
AP		EQ 5MG BASE/ML	N75484 001 JUN 20, 2000
AP	TAYLOR	EQ 5MG BASE/ML	N75481 001 JUN 30, 2000
AP	TAYLOR PHARMA	EQ 1MG BASE/ML	N75494 001 JUN 30, 2000
AP		EQ 5MG BASE/ML	N75494 002 JUN 30, 2000

VERSED

AP	+ HLR	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987
AP	+	EQ 5MG BASE/ML	N18654 001 DEC 20, 1985
AP	* ROCHE	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987
AP	*	EQ 5MG BASE/ML	N18654 001 DEC 20, 1985

MIFEPRISTONE

TABLET; ORAL
MIFEPREX

+	POPULATION COUNCIL	200MG	N20687 001 SEP 28, 2000

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		MINOCIN		
AB	*	LEDERLE	EQ 100MG BASE	N50649 002 MAY 31, 1990
AB			EQ 100MG BASE	N50649 002 MAY 31, 1990
		MINOCYCLINE HCL		
AB	*	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
AB			EQ 75MG BASE	N63065 002 JUN 10, 1999
AB			EQ 100MG BASE	N63065 001 DEC 30, 1991
AB	+		EQ 100MG BASE	N63065 001 DEC 30, 1991
AB		RANBAXY	EQ 50MG BASE	N65062 001 NOV 30, 2000
AB			EQ 75MG BASE	N65062 002 NOV 30, 2000
AB			EQ 100MG BASE	N65062 003 NOV 30, 2000

MIRTAZAPINE

TABLET; ORAL

		REMERON		
> DLT >		ORGANON	15MG	N20415 001 JUN 14, 1996
> DLT >	*		45MG	N20415 001 MAR 17, 1997
> DLT >				
> ADD >	+		15MG	N20415 001 JUN 14, 1996
> ADD >				
> ADD >			45MG	N20415 003 MAR 17, 1997
> ADD >				

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

		SINGULAIR		
		MERCK	EQ 4MG BASE	N20830 002 MAR 03, 2000

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

		MORPHINE SULFATE		
AB		ENDO PHARMS	100MG	N75295 004 SEP 15, 2000
AB			200MG	N75295 005 SEP 15, 2000
AB		ESI LEDERLE	15MG	N75407 001 JAN 28, 2000

NABUMETONE

TABLET; ORAL

		NABUMETONE		
AB		COPLEY PHARM	750MG	N75179 001 JUN 06, 2000
AB		TEVA	500MG	N75189 001 MAY 26, 2000
		RELAFEN		
AB		SMITHKLINE BEECHAM	500MG	N19583 001 DEC 24, 1991
AB	+		750MG	N19583 002 DEC 24, 1991
			500MG	N19583 001 DEC 24, 1991
	*		750MG	N19583 002 DEC 24, 1991

NADOLOL

TABLET; ORAL

		CORGARD		
AB		APOTHECON	40MG	N18063 001
AB	+		40MG	N18063 001

NAFCILLIN SODIUM

INJECTABLE; INJECTION

		NALLPEN		
AP		SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62755 001 DEC 19, 1986
AP			EQ 2GM BASE/VIAL	N62755 002 DEC 19, 1986
	@		EQ 1GM BASE/VIAL	N62755 001 DEC 19, 1986

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NALLPEN
@ SMITHKLINE BEECHAM EQ 2GM BASE/VIAL N62755 002 DEC 19, 1986

TABLET; ORAL
UNIPEN
+ WYETH AYERST EQ 500MG BASE N50462 001
@ EQ 500MG BASE N50462 001

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX
+ BAXTER PHARM PROD EQ 0.1MG BASE/ML N20459 001 APR 17, 1995
+ EQ 1MG BASE/ML N20459 002 APR 17, 1995
+ OHMEDA EQ 0.1MG BASE/ML N20459 001 APR 17, 1995
+ EQ 1MG BASE/ML N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
AP ASTRAZENECA 0.02MG/ML N72081 001 APR 11, 1989 > ADD >
AP 0.4MG/ML N72086 001 APR 11, 1989 > ADD > > ADD >
AP 1MG/ML N72091 001 APR 11, 1989 > ADD > > ADD >
@ 0.02MG/ML N72081 001 APR 11, 1989 > ADD > > ADD >
@ 0.4MG/ML N72086 001 APR 11, 1989
@ 1MG/ML N72091 001 APR 11, 1989

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES
AB RANBAXY EQ 0.5MG BASE; EQ 50MG BASE N75523 001 MAR 17, 2000

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL
AB EON 50MG N75434 001 MAR 08, 2000

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN
AB GENEVA PHARMS TECH 375MG N75061 001 FEB 18, 1998
AB 500MG N75061 002 FEB 18, 1998
AB INVAMED 375MG N75061 001 FEB 18, 1998
AB 500MG N75061 002 FEB 18, 1998

NATEGLINIDE

TABLET; ORAL
STARLIX
NOVARTIS 60MG N21204 001 DEC 22, 2000
+ 120MG N21204 002 DEC 22, 2000

NIACIN

TABLET; ORAL
NIACIN
AA GLOBAL PHARM 500MG N83115 001
@ IMPAX LABS 500MG N83115 001
NIACOR
AA UPSHER SMITH 500MG N40378 001 MAY 03, 2000

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

		ADALAT CC			
	AB	+ BAYER	30MG		N20198 001 APR 21, 1993
	BC	*	30MG		N20198 001 APR 21, 1993
		NIFEDIPINE			
> ADD >	AB	BIOVAIL	30MG		N75269 001 DEC 04, 2000
> ADD >	AB		60MG		N75269 002 DEC 04, 2000
	AB		60MG		N75289 001 SEP 27, 2000
	AB	ELAN PHARM	30MG		N75128 001 MAR 10, 2000
		PROCARDIA XL			
	AB	+ PFIZER	60MG		N19684 002 SEP 06, 1989
	BC	*	60MG		N19684 002 SEP 06, 1989

NILUTAMIDE

TABLET; ORAL

		NILANDRON			
> ADD >		AVENTIS PHARMS	50MG		N20169 001 SEP 19, 1996
> ADD >	+		150MG		N20169 002 APR 30, 1999
> DLT >	*	HOECHST MARION RSSL	50MG		N20169 001 SEP 19, 1996

NITROFURAZONE

CREAM; TOPICAL

		FURACIN			
	*	ROBERTS LABS	0.2%		N83789 001
	+	SHIRE	0.2%		N83789 001

OINTMENT; TOPICAL

		FURACIN			
	AT	* ROBERTS LABS	0.2%		N05795 001
	AT	+ SHIRE	0.2%		N05795 001

NITROGLYCERIN

INJECTABLE; INJECTION

		NITRO IV			
	AP	* BOHL BOSKAMP	5MG/ML		N18672 002 AUG 30, 1983
		@	5MG/ML		N18672 002 AUG 30, 1983

TABLET; SUBLINGUAL

		NITROSTAT			
		PARKE DAVIS	0.3MG		N21134 001 MAY 01, 2000
			0.4MG		N21134 002 MAY 01, 2000
		+	0.6MG		N21134 003 MAY 01, 2000

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

		NORTRIPTYLINE HCL			
> ADD >	AB	GENEVA PHARMS TECH	EQ 10MG BASE		N74835 001 JUN 30, 1997
> ADD >	AB		EQ 25MG BASE		N74835 002 JUN 30, 1997
> ADD >	AB		EQ 50MG BASE		N74835 003 JUN 30, 1997
> ADD >	AB		EQ 75MG BASE		N74835 004 JUN 30, 1997
> DLT >	AB	INVAMED	EQ 10MG BASE		N74835 001 JUN 30, 1997
> DLT >	AB		EQ 25MG BASE		N74835 002 JUN 30, 1997
> DLT >	AB		EQ 50MG BASE		N74835 003 JUN 30, 1997
> DLT >	AB		EQ 75MG BASE		N74835 004 JUN 30, 1997
	AB	TARO	EQ 10MG BASE		N75520 004 MAY 08, 2000
	AB		EQ 25MG BASE		N75520 003 MAY 08, 2000
	AB		EQ 50MG BASE		N75520 001 MAY 08, 2000
	AB		EQ 75MG BASE		N75520 002 MAY 08, 2000

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL
NORTRIPTYLINE HCL

AA	PHARM ASSOC	**EQ 10MG BASE/5ML**	**N75606 001** AUG 28, 2000

NYSTATIN

TABLET; VAGINAL
NYSTATIN

AT	ODYSSEY PHARMS	**100,000 UNITS**	**N62615 001** OCT 17, 1985
AT	SIDMAK LABS NJ	100,000 UNITS	N62615 001 OCT 17, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN

	NOVARTIS	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991
+		EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
+		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

SANDOSTATIN LAR

	NOVARTIS	EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998
+		EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
+		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA

	LILLY	2.5MG	N20592 001 SEP 30, 1996
*		10MG	N20592 004 SEP 30, 1996
*		15MG	N20592 005 SEP 09, 1997
+		2.5MG	N20592 001 SEP 30, 1996
		10MG	N20592 004 SEP 30, 1996
+		15MG	N20592 005 SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
ZYPREXA ZYDIS

	LILLY	5MG	N21086 001 APR 06, 2000
		10MG	N21086 002 APR 06, 2000
		15MG	N21086 003 APR 06, 2000
+		20MG	N21086 004 APR 06, 2000

ORLISTAT

CAPSULE; ORAL
XENICAL

+	HLR	120MG	N20766 001 APR 23, 1999
*	ROCHE	120MG	N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE

AB	EON	**100MG**	**N40327 001** FEB 15, 2000
AB	GENEVA PHARMS TECH	**100MG**	**N40284 001** JUN 19, 1998
AB	IMPAX PHARM	**100MG**	**N40368 001** JUN 23, 2000
AB	INVAMED	**100MG**	**N40284 001** JUN 19, 1998

OSELTAMIVIR PHOSPHATE

> ADD >	POWDER FOR RECONSTITUTION; ORAL			
> ADD >	TAMIFLU			
> ADD >	+	ROCHE	EQ 12MG BASE/ML	N21246 001
> ADD >				DEC 14, 2000

OXACILLIN SODIUM

	INJECTABLE; INJECTION			
	BACTOCILL			
AP	*	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61334 009
				MAR 26, 1982
AP	*		EQ 1GM BASE/VIAL	N61334 006
				MAR 26, 1982
AP	*		EQ 2GM BASE/VIAL	N61334 007
				MAR 26, 1982
AP	*		EQ 4GM BASE/VIAL	N61334 008
				MAR 26, 1982
AP	*		EQ 10GM BASE/VIAL	N61334 010
	@		EQ 500MG BASE/VIAL	N61334 009
				MAR 26, 1982
	@		EQ 1GM BASE/VIAL	N61334 006
				MAR 26, 1982
	@		EQ 2GM BASE/VIAL	N61334 007
				MAR 26, 1982
	@		EQ 4GM BASE/VIAL	N61334 008
				MAR 26, 1982
	@		EQ 10GM BASE/VIAL	N61334 010
	OXACILLIN SODIUM			
AP		APOTHECON	EQ 500MG BASE/VIAL	N61490 002
AP	+		EQ 500MG BASE/VIAL	N61490 002
AP			EQ 10GM BASE/VIAL	N61490 006
				MAY 09, 1991
AP	+		EQ 10GM BASE/VIAL	N61490 006
				MAY 09, 1991
AP		MARSAM	EQ 4GM BASE/VIAL	N62856 005
				OCT 26, 1988
			EQ 4GM BASE/VIAL	N62856 005
				OCT 26, 1988

OXCARBAZEPINE

	TABLET; ORAL			
	TRILEPTAL			
		NOVARTIS	150MG	N21014 001
				JAN 14, 2000

OXCARBAZEPINE

	TABLET; ORAL			
	TRILEPTAL			
		NOVARTIS	300MG	N21014 002
				JAN 14, 2000
	+		600MG	N21014 003
				JAN 14, 2000

OXYBUTYNIN CHLORIDE

	TABLET, EXTENDED RELEASE; ORAL			
	DITROPAN XL			
AB	*	ALZA	5MG	N20897 001
				DEC 16, 1998
	+		5MG	N20897 001
				DEC 16, 1998

OXYCODONE HYDROCHLORIDE

	TABLET; ORAL			
	ROXICODONE			
		ROXANE	15MG	N21011 001
				AUG 31, 2000
	+		30MG	N21011 002
				AUG 31, 2000
	TABLET, EXTENDED RELEASE; ORAL			
	OXYCONTIN			
BX	*	PURDUE PHARMA	10MG	N20553 001
				DEC 12, 1995
	+	PURDUE PHARMA LP	10MG	N20553 001
				DEC 12, 1995
	+		160MG	N20553 005
				MAR 15, 2000
	ROXICODONE			
BX		ROXANE	10MG	N20932 001
				OCT 26, 1998
	*		30MG	N20932 002
				OCT 26, 1998
	@		10MG	N20932 001
				OCT 26, 1998
	@		30MG	N20932 002
				OCT 26, 1998

PACLITAXEL

INJECTABLE; INJECTION

	PACLITAXEL		
AP	BAKER NORTON	6MG/ML	N75184 001 SEP 15, 2000
	TAXOL		
AP	+ BRISTOL MYERS SQUIBB	6MG/ML	N20262 001 DEC 29, 1992
	*	6MG/ML	N20262 001 DEC 29, 1992

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

	PROTONIX		
	+ WYETH AYERST	EQ 40MG BASE	N20987 001 FEB 02, 2000

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PAXIL CR		
> ADD >	+ SMITHKLINE BEECHAM	EQ 37.5MG BASE	N20936 003 DEC 06, 2000
> ADD >			

PEMOLINE

TABLET; ORAL

	PEMOLINE		
AB	AMIDE PHARM	18.75MG	N75595 001 FEB 28, 2000
AB		37.5MG	N75595 002 FEB 28, 2000
AB		75MG	N75595 003 FEB 28, 2000
AB	COPLEY PHARM	18.75MG	N75030 003 FEB 22, 2000
AB	GENEVA PHARMS TECH	18.75MG	N75286 001 DEC 27, 1999
AB		37.5MG	N75286 002 JUN 30, 1999
AB		75MG	N75286 003 JUN 30, 1999
AB	INVAMED	18.75MG	N75286 001 DEC 27, 1999

PEMOLINE

TABLET; ORAL

	PEMOLINE		
AB	INVAMED	37.5MG	N75286 002 JUN 30, 1999
AB		75MG	N75286 003 JUN 30, 1999
AB	VINTAGE PHARMS	18.75MG	N75328 001 APR 19, 2000
AB		37.5MG	N75328 002 APR 19, 2000
AB		75MG	N75328 003 APR 19, 2000
AB	WATSON LABS	37.5MG	N75287 002 SEP 18, 2000
AB		75MG	N75287 003 SEP 18, 2000

TABLET, CHEWABLE; ORAL

	CYLERT		
AB	+ ABBOTT	37.5MG	N17703 001
	*	37.5MG	N17703 001
	PEMOLINE		
AB	AMIDE PHARM	37.5MG	N75678 001 JUL 26, 2000
AB	COPLEY PHARM	37.5MG	N75555 001 FEB 18, 2000

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

	BICILLIN L-A		
BC	+ KING PHARMS	600,000 UNITS/ML	N50141 001
	+	300,000 UNITS/ML	N50141 003
BC	+ WYETH AYERST	600,000 UNITS/ML	N50141 001
	*	300,000 UNITS/ML	N50141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	BICILLIN C-R		
	+ KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML	N50138 002
	+	300,000 UNITS/ML; 300,000 UNITS/ML	N50138 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION
BICILLIN C-R

*	WYETH AYERST	150,000 UNITS/ML; 150,000 UNITS/ML	N50138 002
*		300,000 UNITS/ML; 300,000 UNITS/ML	N50138 001

BICILLIN C-R 900/300

+	KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML	N50138 003
*	WYETH AYERST	900,000 UNITS/2ML; 300,000 UNITS/2ML	N50138 003

PENICILLIN G PROCAINE

INJECTABLE; INJECTION
WYCILLIN

AP	KING PHARMS	**300,000 UNITS/ML**	**N60101 002**
AP		**600,000 UNITS/ML**	**N60101 001**
AP	WYETH AYERST	300,000 UNITS/ML	N60101 002
AP		600,000 UNITS/ML	N60101 001

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT

AP	ARMOUR PHARM	300MG/VIAL	N73447 001 APR 28, 1994
	@	300MG/VIAL	N73447 001 APR 28, 1994

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	IMPAX LABS	**400MG**	**N75093 001 AUG 10, 1999**
AB	IMPAX PHARM	400MG	N75093 001 AUG 10, 1999

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

+	US ARMY	50%;50%	N21084 001 FEB 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL
PERMAX

	LILLY	EQ 0.05MG BASE	N19385 001 DEC 30, 1988
*		EQ 1MG BASE	N19385 003 DEC 30, 1988
+		EQ 0.05MG BASE	N19385 001 DEC 30, 1988
		EQ 1MG BASE	N19385 003 DEC 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

@	SOLVAY	2MG	N20184 001 DEC 30, 1993
@		4MG	N20184 002 DEC 30, 1993
@		8MG	N20184 003 DEC 30, 1993
	SOLVAY PHARMA	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM

AA	AMARIN PHARMS	**35MG**	**N85272 001**
AA	CARNRICK	35MG	N85272 001

CAM-METRAZINE

AA	CAMALL	**35MG**	**N83922 001**

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

	CAM-METRAZINE		
AA	+ CAMALL	**35MG**	**N83922 001**
	PLEGINE		
AA	+ WYETH AYERST	35MG	N12248 001
	@	35MG	N12248 001

PHYTONADIONE

INJECTABLE; INJECTION

	KONAKION		
BP	ROCHE	1MG/0.5ML	N11745 001
BP		10MG/ML	N11745 003
	@	1MG/0.5ML	N11745 001
	@	10MG/ML	N11745 003

PIROXICAM

CAPSULE; ORAL

	PIROXICAM		
AB	ROXANE	10MG	N73651 001 FEB 26, 1993
AB		20MG	N73651 002 FEB 26, 1993
	@	10MG	N73651 001 FEB 26, 1993
	@	20MG	N73651 002 FEB 26, 1993

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	COLYTE WITH FLAVOR PACKS		
AA	SCHWARZ PHARMA	**240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT**	**N18983 012** OCT 08, 1998

PORFIMER SODIUM

INJECTABLE; INJECTION

	PHOTOFRIN		
	+ AXCAN SCANDIPHARM	75MG/VIAL	N20451 001 DEC 27, 1995

PORFIMER SODIUM

INJECTABLE; INJECTION

	PHOTOFRIN		
	* QLT	75MG/VIAL	N20451 001 DEC 27, 1995

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	K-DUR 10		
AB	+ KEY PHARMS	**10MEQ**	**N19439 002** JUN 13, 1986
BC	*	10MEQ	N19439 002 JUN 13, 1986
	KLOR-CON M10		
AB	UPSHER SMITH	**10MEQ**	**N74726 002** AUG 09, 2000

PREDNISOLONE

SYRUP; ORAL

	PREDNISOLONE		
AA	COPLEY PHARM	**15MG/5ML**	**N40322 001** JAN 19, 2000

TABLET; ORAL

	PREDNISOLONE		
BX	GLOBAL PHARM	5MG	N80780 001
	@ IMPAX LABS	5MG	N80780 001
BX	PHOENIX LABS NY	5MG	N80322 001
	@	5MG	N80322 001
BX	ROXANE	5MG	N80327 002
	@	5MG	N80327 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

	ORAPRED		
	+ ASCENT PEDS	EQ 15MG BASE/5ML	N75117 001 DEC 14, 2000

SOLUTION/DROPS; OPHTHALMIC

	PREDNISOLONE SODIUM PHOSPHATE		
AT	ALCON UNIVERSAL	**EQ 0.11% PHOSPHATE**	**N81043 001** OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.9% PHOSPHATE	N81044 001 OCT 24, 1991
AT	STERIS	EQ 0.11% PHOSPHATE	N81043 001 OCT 24, 1991
AT		EQ 0.9% PHOSPHATE	N81044 001 OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.23% PHOSPHATE;10%	N73630 001 MAY 27, 1993
AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001 MAY 27, 1993

PREDNISONE

SYRUP; ORAL
LIQUID PRED

*	MURO	5MG/5ML	N87611 002 SEP 07, 1982
@		5MG/5ML	N87611 002 SEP 07, 1982

TABLET; ORAL
PREDNICEN-M

AB	CENT PHARMS	5MG	N84655 001
@	SCHWARZ PHARMA	5MG	N84655 001

PREDNISONE

AB	GLOBAL PHARM	5MG	N80782 001
@	IMPAX LABS	5MG	N80782 001
BX	PHOENIX LABS NY	5MG	N80321 001
BX		20MG	N83807 001
@		5MG	N80321 001
@		20MG	N83807 001

PRIMIDONE

TABLET; ORAL
MYSOLINE

*	ELAN PHARMA	50MG	N09170 003

PRIMIDONE

TABLET; ORAL
MYSOLINE

	ELAN PHARMA	50MG	N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR

AB	* PARKEDALE	500MG	N86065 001
AB	*	750MG	N87510 001 APR 01, 1982
AB	*	1GM	N88489 001 JAN 16, 1985
	@	500MG	N86065 001
	@	750MG	N87510 001 APR 01, 1982
	@	1GM	N88489 001 JAN 16, 1985

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPRO

AB	PADDOCK	25MG	N40246 001 JUN 28, 2000

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998
		200MG	N19781 002 OCT 15, 1999
*		300MG	N19781 003 OCT 15, 1999
	UNIMED PHARMS	100MG	N19781 001 MAY 14, 1998
+		200MG	N19781 002 OCT 15, 1999
@		300MG	N19781 003 OCT 15, 1999

INJECTABLE; INJECTION
PROGESTERONE

> DLT > AO	* LILLY	50MG/ML	N09238 001

PROGESTERONE

INJECTABLE; INJECTION
PROGESTERONE

> ADD >		@ LILLY	50MG/ML	N09238 001
> DLT >	AO	* STERIS	50MG/ML	N17362 002
> ADD >		+	50MG/ML	N17362 002

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	ABBOTT	25MG/ML	N40372 001 JUN 08, 2000
AP		50MG/ML	N40372 002 JUN 08, 2000

SUPPOSITORY; RECTAL
PHENERGAN

> DLT >	BR	WYETH AYERST	25MG	N10926 001
> ADD >	BR	+	25MG	N10926 001

TABLET; ORAL
PROMETHAZINE HCL

> DLT >	BP	GLOBAL PHARM	25MG	N84214 002 JUL 07, 1982
> DLT >				
> ADD >		@ IMPAX LABS	25MG	N84214 002 JUL 07, 1982
> ADD >				

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL
PROPAFENONE HCL

AB	WATSON LABS	150MG	N75203 001 OCT 24, 2000
AB		225MG	N75203 002 OCT 24, 2000

RYTHMOL

AB	KNOLL PHARM	150MG	N19151 001 NOV 27, 1989
AB		225MG	N19151 003 NOV 20, 1992
		150MG	N19151 001 NOV 27, 1989
		225MG	N19151 003 NOV 20, 1992

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

BP	*	ROBERTS LABS	7.5MG	N08732 003
BP	*		15MG	N08732 002
BP	+	SHIRE	7.5MG	N08732 003
BP	+		15MG	N08732 002

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
PROPARACAINE HCL

AT	TAYLOR PHARMA	0.5%	N40277 001 MAR 16, 2000

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB	GENSIA SICOR PHARMS	10MG/ML	N75392 001 SEP 19, 2000

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL

AP	+	WYETH AYERST	1MG/ML	N16419 001
	*		1MG/ML	N16419 001

PROPRANOLOL HCL

AP	BEDFORD	1MG/ML	N75792 001 AUG 29, 2000

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL
VENTAIRE

	@ AVENTIS PHARMS	2MG	N83459 001
	* HOECHST MARION RSSL	2MG	N83459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
VIVACTIL

AB	MERCK	5MG	N16012 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
VIVACTIL

AB	*	MERCK	10MG	N16012 002
AB		SIDMAK LABS	5MG	N16012 001
AB	+		10MG	N16012 002

QUINIDINE POLYGALACTURONATE

TABLET; ORAL
CARDIOQUIN

	*	PURDUE FREDERICK	275MG	N11642 002
	@		275MG	N11642 002

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB		PHARMAVITE	200MG	N84627 001
	@		200MG	N84627 001

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HCL

> DLT >	AB		CHEMINOR DRUGS	EQ 150MG BASE	N75742 001
> DLT >					NOV 29, 2000
> DLT >	AB			EQ 300MG BASE	N75742 002
> DLT >					NOV 29, 2000
> ADD >	AB		DR REDDYS LABS LTD	EQ 150MG BASE	N75742 001
> ADD >					NOV 29, 2000
> ADD >	AB			EQ 300MG BASE	N75742 002
> ADD >					NOV 29, 2000
	AB		GENPHARM	EQ 150MG BASE	N75564 001
					OCT 27, 2000
	AB			EQ 300MG BASE	N75564 002
					OCT 27, 2000

TABLET; ORAL
RANITIDINE

AB		RANBAXY	EQ 150MG BASE	N75439 001
				APR 19, 2000
AB			EQ 300MG BASE	N75439 002
				APR 19, 2000

RESERPINE

TABLET; ORAL
RESERPINE

BP		GLOBAL PHARM	0.1MG	N09627 001
BP			0.25MG	N09627 002
	@	IMPAX LABS	0.1MG	N09627 001
	@		0.25MG	N09627 002

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

		PROCTER AND GAMBLE	5MG	N20835 002
				APR 14, 2000

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

		NOVARTIS	EQ 1.5MG BASE	N20823 003
				APR 21, 2000
			EQ 3MG BASE	N20823 004
				APR 21, 2000
			EQ 4.5MG BASE	N20823 005
				APR 21, 2000
	+		EQ 6MG BASE	N20823 006
				APR 21, 2000

SOLUTION; ORAL
EXELON

	+	NOVARTIS	EQ 2MG BASE/ML	N21025 001
				APR 21, 2000

ROFECOXIB

TABLET; ORAL
VIOXX

	*	MERCK	25MG	N21042 002
				MAY 20, 1999
			25MG	N21042 002
				MAY 20, 1999
	+		50MG	N21042 003
				FEB 25, 2000

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

AT	ZENITH GOLDLINE	2.5%	N85777 001
	@	2.5%	N85777 001

SEVELAMER HYDROCHLORIDE

TABLET; ORAL
RENAGEL

	GELTEX	400MG	N21179 001 JUL 12, 2000
+		800MG	N21179 002 JUL 12, 2000

SIROLIMUS

TABLET; ORAL
RAPAMUNE

+	WYETH AYERST	1MG	N21110 001 AUG 25, 2000

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18

	@ NYCOMED AMERSHAM	2mCi/ML	N17042 001

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE

	BRACCO	1-130mCi	N10929 001
		1-150mCi	N10929 003
+		1-130mCi	N10929 001
+		1-150mCi	N10929 003
	SODIUM IODIDE I 131		
	CIS	100 uCi	N17316 002
+		100 uCi	N17316 002
	MALLINCKRODT	15-100 uCi	N16517 002
		0.8-100mCi	N16517 001
+		15-100 uCi	N16517 002
+		0.8-100mCi	N16517 001

SODIUM IODIDE, I-131

SOLUTION; ORAL
IODOTOPE

	BRACCO	7-106mCi/BOT	N10929 002
+		7-106mCi/BOT	N10929 002
	SODIUM IODIDE I 131		
	CIS	50mCi/ML	N17315 001
+		50mCi/ML	N17315 001
	MALLINCKRODT	3.5-150mCi/VIAL	N16515 001
+		3.5-150mCi/VIAL	N16515 001

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
VISICOL

+	INKINE	0.398GM;1.102GM	N21097 001 SEP 21, 2000

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN

	NOVO NORDISK	5MG/1.5ML	N21148 001 JUN 20, 2000
		10MG/1.5ML	N21148 002 JUN 20, 2000
+		15MG/1.5ML	N21148 003 JUN 20, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

AB	BERLEX LABS	80MG	N19865 001 OCT 30, 1992
AB		120MG	N19865 005 APR 20, 1994
AB +		160MG	N19865 002 OCT 30, 1992
AB		240MG	N19865 003 OCT 30, 1992
		80MG	N19865 001 OCT 30, 1992

SOTALOL HYDROCHLORIDE

TABLET; ORAL

		BETAPACE		
		BERLEX LABS	120MG	N19865 005 APR 20, 1994
		*	160MG	N19865 002 OCT 30, 1992
			240MG	N19865 003 OCT 30, 1992
		BETAPACE AF		
		BERLEX LABS	80MG	N21151 001 FEB 22, 2000
			120MG	N21151 002 FEB 22, 2000
		+	160MG	N21151 003 FEB 22, 2000
		SOTALOL HCL		
	AB	EON	80MG	N75366 001 MAY 01, 2000
	AB		120MG	N75366 002 MAY 01, 2000
	AB		160MG	N75366 003 MAY 01, 2000
	AB		240MG	N75366 004 MAY 01, 2000
	AB	GENPHARM	80MG	N75237 001 MAY 01, 2000
	AB		120MG	N75237 002 MAY 01, 2000
	AB		160MG	N75237 003 MAY 01, 2000
	AB		240MG	N75237 004 MAY 01, 2000
	AB	IMPAX PHARM	80MG	N75663 001 NOV 07, 2000
	AB		120MG	N75663 002 NOV 07, 2000
	AB		160MG	N75663 003 NOV 07, 2000
	AB		240MG	N75663 004 NOV 07, 2000
> ADD > > ADD >	AB	MYLAN	80MG	N75725 001 DEC 19, 2000
> ADD > > ADD >	AB		120MG	N75725 002 DEC 19, 2000
> ADD > > ADD >	AB		160MG	N75725 003 DEC 19, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL

		SOTALOL HCL		
> ADD > > ADD	AB	MYLAN	240MG	N75725 004 DEC 19, 2000
	AB	TEVA	80MG	N75429 001 MAY 01, 2000
	AB		120MG	N75429 002 MAY 01, 2000
	AB		160MG	N75429 003 MAY 01, 2000
	AB		240MG	N75429 004 MAY 01, 2000
	AB	WATSON LABS	80MG	N75238 001 JUL 13, 2000
	AB		120MG	N75238 002 JUL 13, 2000
	AB		160MG	N75238 003 JUL 13, 2000
	AB		240MG	N75238 004 JUL 13, 2000

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

	METASTRON		
	NYCOMED AMERSHAM	1mCi/ML	N20134 001 JUN 18, 1993
+		1mCi/ML	N20134 001 JUN 18, 1993

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	OCUSULF-10		
AT	MIZA PHARMS USA	10%	N80660 001
AT	OPTOPICS	10%	N80660 001
	OCUSULF-30		
	@ MIZA PHARMS USA	30%	N80660 002
	@ OPTOPICS	30%	N80660 002
	SULFACETAMIDE SODIUM		
AT	ALCON UNIVERSAL	10%	N89560 001 OCT 18, 1988
AT	STERIS	10%	N89560 001 OCT 18, 1988

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

AB	GLOBAL PHARM	500MG	N80109 001
	@ IMPAX LABS	500MG	N80109 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

	FIRST HORIZON	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
	+	EQ 40MG BASE	N20070 004 SEP 09, 1993
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
	*	EQ 40MG BASE	N20070 004 SEP 09, 1993

TACROLIMUS

> ADD >	OINTMENT; TOPICAL			
> ADD >	PROTOPIC			
> ADD >	FUJISAWA HLTHCARE	0.03%	N50777 001 DEC 08, 2000	
> ADD >	+	0.1%	N50777 002 DEC 08, 2000	

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

	@ MYLAN	EQ 10MG BASE	N74732 001 JUN 26, 2000	
> ADD >	@ PHARMACHEMIE	EQ 10MG BASE	N74539 001 MAY 31, 2000	> ADD >

TAZAROTENE

CREAM; TOPICAL
TAZORAC

	ALLERGAN	0.05%	N21184 001 SEP 29, 2000
	+	0.1%	N21184 002 SEP 29, 2000

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M TSC

AP	NYCOMED AMERSHAM	N/A	N17784 001
	@	N/A	N17784 001

TELMISARTAN

TABLET; ORAL
MICARDIS

	+ BOEHRINGER INGELHEIM	20MG	N20850 003 APR 04, 2000

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 1MG BASE	N75667 001 JUL 28, 2000
AB		EQ 2MG BASE	N75667 002 JUL 28, 2000
AB		EQ 5MG BASE	N75667 003 JUL 28, 2000
AB		EQ 10MG BASE	N75667 004 JUL 28, 2000
AB	MYLAN	EQ 1MG BASE	N75140 002 FEB 11, 2000
AB		EQ 2MG BASE	N75140 003 FEB 11, 2000
AB		EQ 5MG BASE	N75140 001 FEB 11, 2000
AB		EQ 10MG BASE	N75140 004 FEB 11, 2000
> ADD > AB	MYLAN TECHNOLOGIES	EQ 1MG BASE	N75384 001 DEC 01, 2000 > ADD >

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

> ADD >	AB	MYLAN TECHNOLOGIES	EQ 2MG BASE	N75384 002 DEC 01, 2000
> ADD >	AB		EQ 5MG BASE	N75384 003 DEC 01, 2000
> ADD >	AB		EQ 10MG BASE	N75384 004 DEC 01, 2000

TABLET; ORAL
TERAZOSIN HCL

	AB	INVAMED	EQ 1MG BASE	N74657 001 APR 28, 2000
	AB		EQ 2MG BASE	N74657 002 APR 28, 2000
	AB		EQ 5MG BASE	N74657 003 APR 28, 2000
	AB		EQ 10MG BASE	N74657 004 APR 28, 2000
	AB	NOVOPHARM	EQ 1MG BASE	N74446 001 MAY 18, 2000
	AB		EQ 2MG BASE	N74446 002 MAY 18, 2000
	AB		EQ 5MG BASE	N74446 003 MAY 18, 2000
	AB		EQ 10MG BASE	N74446 004 MAY 18, 2000
	AB	ZENITH GOLDLINE	EQ 1MG BASE	N74530 001 APR 21, 2000
	AB		EQ 2MG BASE	N74530 002 APR 21, 2000
	AB		EQ 5MG BASE	N74530 003 APR 21, 2000
	AB		EQ 10MG BASE	N74530 004 APR 21, 2000

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION
BRETHAIRE

		NOVARTIS	0.2MG/INH	N18762 001 AUG 17, 1984
	@		0.2MG/INH	N18762 001 AUG 17, 1984

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX	*	THERATECH	5MG/24HR	N20489 002 MAY 02, 1997
	*		2.5MG/24HR	N20489 001 SEP 29, 1995
BX	+	WATSON LABS	5MG/24HR	N20489 002 MAY 02, 1997
	+		2.5MG/24HR	N20489 001 SEP 29, 1995

GEL; TOPICAL
ANDROGEL

	+	UNIMED PHARMS	1%	N21015 001 FEB 28, 2000

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SLO-PHYLLIN

	@	AVENTIS	60MG	N85206 001 MAY 24, 1982
	@		125MG	N85203 001 MAY 24, 1982
	@		250MG	N85205 001 MAY 24, 1982
BC		RHONE POULENC RORER	125MG	N85203 001 MAY 24, 1982
BC			250MG	N85205 001 MAY 24, 1982
			60MG	N85206 001 MAY 24, 1982

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BETALIN S

AP	*	LILLY	100MG/ML	N80853 001
	@		100MG/ML	N80853 001

THIAMINE HCL

AP		AM PHARM PARTNERS	100MG/ML	N80556 001
AP	+		100MG/ML	N80556 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL

> DLT >		ABBOTT	4MG	N20646 001
> DLT >				SEP 30, 1997
> DLT >			12MG	N20646 002
> DLT >				SEP 30, 1997
> DLT >			16MG	N20646 003
> DLT >				SEP 30, 1997
> DLT >		+	20MG	N20646 004
> DLT >				SEP 30, 1997
> ADD >		CEPHALON	4MG	N20646 001
> ADD >				SEP 30, 1997
> ADD >			12MG	N20646 002
> ADD >				SEP 30, 1997
> ADD >			16MG	N20646 003
> ADD >				SEP 30, 1997
> ADD >		+	20MG	N20646 004
> ADD >				SEP 30, 1997

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HCL

	AB	DANBURY PHARMA	250MG	N75309 001
				APR 26, 2000
> ADD >	AB	GENEVA PHARMS TECH	250MG	N75318 001
> ADD >				AUG 20, 1999
> DLT >	AB	INVAMED	250MG	N75318 001
> DLT >				AUG 20, 1999

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	NOVEX	EQ 0.25% BASE	N75411 001
			SEP 08, 2000
AT		EQ 0.5% BASE	N75412 001
			SEP 08, 2000

TABLET; ORAL
TIMOLOL MALEATE

AB	NOVOPHARM	5MG	N72648 001
			JUN 16, 1993
AB		10MG	N72649 001
			JUN 16, 1993

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

AB	NOVOPHARM	20MG	N72650 001
			JUN 16, 1993
	@	5MG	N72648 001
			JUN 16, 1993
	@	10MG	N72649 001
			JUN 16, 1993
	@	20MG	N72650 001
			JUN 16, 1993

TINZAPARIN SODIUM

INJECTABLE; INJECTION
INNOHEP

+	DUPONT PHARMA	20,000 IU/ML	N20484 001
			JUL 14, 2000

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
ZANAFLEX

ELAN PHARMA	EQ 2MG BASE	N20397 002
		FEB 04, 2000

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	CHELSEA LABS	500MG	N86109 001
AB +		500MG	N86109 001
AB +	ECN	500MG	N12678 001
@		500MG	N12678 001

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

> ADD >	+ PHARMACIA AND UPJOHN	2MG	N21228 001
> ADD >			DEC 22, 2000
> ADD >	+	4MG	N21228 002
> ADD >			DEC 22, 2000

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX SPRINKLE

		JOHNSON RW	25MG	N20844 002 OCT 26, 1998
	*		50MG	N20844 003 OCT 26, 1998
	+		25MG	N20844 002 OCT 26, 1998
	@		50MG	N20844 003 OCT 26, 1998

TORSEMIDE

TABLET; ORAL
DEMADEX

> DLT >		ROCHE	20MG	N20136 003 AUG 23, 1993
> DLT >	*		100MG	N20136 004 AUG 23, 1993
> ADD >	+		20MG	N20136 003 AUG 23, 1993
> ADD >			100MG	N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL
RENOVA

	+	JOHNSON AND JOHNSON	0.02%	N21108 001 AUG 31, 2000

GEL; TOPICAL
RETIN-A

AB	+	JOHNSON AND JOHNSON	0.025%	N17579 002
BT	*		0.025%	N17579 002

TRETINOIN

AB		SPEAR PHARMS	0.025%	N75529 001 FEB 22, 2000

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
FLUTEX

AT		ZENITH GOLDLINE	0.025%	N85539 001
AT			0.1%	N85539 002
AT			0.5%	N85539 003
	@		0.025%	N85539 001
	@		0.1%	N85539 002
	@		0.5%	N85539 003

TRIATEX

AT		ZENITH GOLDLINE	0.025%	N87430 001 NOV 01, 1988
AT			0.1%	N87429 001 NOV 01, 1988
AT			0.5%	N87428 001 NOV 01, 1988
	@		0.025%	N87430 001 NOV 01, 1988
	@		0.1%	N87429 001 NOV 01, 1988
	@		0.5%	N87428 001 NOV 01, 1988

OINTMENT; TOPICAL
ARISTOCORT A

AT	*	FUJISAWA HLTHCARE	0.5%	N80745 003
AT			0.5%	N80745 003

FLUTEX

AT	*	ZENITH GOLDLINE	0.025%	N87375 001 NOV 01, 1988
AT	*		0.1%	N87377 001 NOV 01, 1988
AT	*		0.5%	N87376 001 NOV 01, 1988
	@		0.025%	N87375 001 NOV 01, 1988
	@		0.1%	N87377 001 NOV 01, 1988
	@		0.5%	N87376 001 NOV 01, 1988

KENALOG

AT	*	APOTHECON	0.025%	N11600 003
AT			0.025%	N11600 003
AT	*		0.1%	N11600 001
AT			0.1%	N11600 001

TRIAMCINOLONE ACETONIDE

AT	*	ALTANA	0.025%	N85691 001
AT			0.025%	N85691 001
AT	*		0.1%	N85691 003

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		ALTANA	0.1%	N85691 003
AT	*		0.5%	N85691 002
AT			0.5%	N85691 002
AT		CLAY PARK	0.025%	N87356 001
AT	+		0.025%	N87356 001
AT			0.1%	N87357 001
AT	+		0.1%	N87357 001
AT			0.5%	N87385 001
AT	+		0.5%	N87385 001

SPRAY, METERED; NASAL
TRI-NASAL

	+	MURO	0.05MG/SPRAY	N20120 001 FEB 04, 2000

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB		ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB			EQ 2MG BASE	N87613 001 NOV 19, 1982
AB			EQ 5MG BASE	N87328 001 NOV 19, 1982
AB			EQ 10MG BASE	N87614 001 NOV 19, 1982
	@		EQ 1MG BASE	N87612 001 NOV 19, 1982
	@		EQ 2MG BASE	N87613 001 NOV 19, 1982
	@		EQ 5MG BASE	N87328 001 NOV 19, 1982
	@		EQ 10MG BASE	N87614 001 NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA		WEST WARD	2MG	N40337 002 FEB 16, 2000

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA		WEST WARD	5MG	N40337 001 FEB 16, 2000

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

		ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995
	+		EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995
	+		EQ 50MG BASE/5ML	N74973 001 JAN 24, 2000

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

	+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993
	*	US BIOSCIENCE	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993

TRIPTORELIN PAMOATE

INJECTABLE; INJECTION
TRELSTAR DEPOT

	+	DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000

TROGLITAZONE

TABLET; ORAL
PRELAY

AB		SANKYO	200MG	N20719 001 JAN 29, 1997
AB			300MG	N20719 001 AUG 04, 1997
AB			400MG	N20719 002 JAN 29, 1997

TROGLITAZONE

TABLET, ORAL
PRELAY
@ SANKYO 200MG N20719 001 JAN 29, 1997
@ 300MG N20719 003 AUG 04, 1997
@ 400MG N20719 002 JAN 29, 1997

REZULIN
AB PARKE DAVIS PHARMS 200MG N20720 001 JAN 29, 1997
AB 300MG N20720 003 AUG 04, 1997
AB 400MG N20720 002 JAN 29, 1997
@ 200MG N20720 001 JAN 29, 1997
@ 300MG N20720 003 AUG 04, 1997
@ 400MG N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICACYL
AT AKORN 0.5% N40314 001 SEP 29, 2000
AT 1% N40315 001 SEP 29, 2000

TROPICAMIDE
AT ALCON UNIVERSAL 1% N89172 001 DEC 28, 1990
AT MIZA PHARMS USA 0.5% N87636 001 JUL 30, 1982
AT 1% N87637 001 AUG 09, 1982
AT OPTOPICS 0.5% N87636 001 JUL 30, 1982
AT 1% N87637 001 AUG 09, 1982
AT STERIS 1% N89172 001 DEC 28, 1990

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ CIBA 0.15% N21214 001 AUG 03, 2000

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL
HELICOSOL
BX * METABOLIC SOLUTIONS 125MG/VIAL N21092 001 DEC 17, 1999
+ 125MG/VIAL N21092 001 DEC 17, 1999

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX
* SERONO 75 IU/AMP N19415 002 SEP 18, 1986
* 150 IU/AMP N19415 003 SEP 18, 1986

METRODIN
@ SERONO 75 IU/AMP N19415 002 SEP 18, 1986
@ 150 IU/AMP N19415 003 SEP 18, 1986

URSODIOL

CAPSULE; ORAL
ACTIGALL
AB + NOVARTIS 300MG N19594 002 DEC 31, 1987
* 300MG N19594 002 DEC 31, 1987

URSODIOL
AB AMIDE PHARM 300MG N75517 001 MAR 14, 2000
AB COPLEY PHARM 300MG N75592 001 MAY 25, 2000

TABLET; ORAL
URSO
* AXCAN 250MG N20675 001 DEC 10, 1997

URSODIOL

TABLET; ORAL
URSO

+	AXCAN SCANDIPHARM	250MG	N20675 001 DEC 10, 1997

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

> ADD >	AA	PHARM ASSOC	250MG/5ML	N75379 001 DEC 15, 2000
> ADD >				
> ADD >	AA	UDL	250MG/5ML	N75782 001 DEC 22, 2000
> ADD >				

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	N75549 001 JUN 13, 2000
AP		20MG/VIAL	N75549 002 JUN 13, 2000

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
COVERA-HS

BC	SEARLE	180MG	N20552 001 FEB 26, 1996
BC +		180MG	N20552 001 FEB 26, 1996
BC		240MG	N20552 002 FEB 26, 1996
BC +		240MG	N20552 002 FEB 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION
VISUDYNE

+	QLT	15MG/VIAL	N21119 001 APR 12, 2000

VITAMIN A

CAPSULE; ORAL
AQUASOL A

AA	+ ASTRAZENECA	50,000 USP UNITS	N83080 001
	+	25,000 USP UNITS	N83080 002
	@	25,000 USP UNITS	N83080 002
	@	50,000 USP UNITS	N83080 001

VITAMIN A

AA	GLOBAL PHARM	50,000 USP UNITS	N80952 001
	@ IMPAX LABS	50,000 USP UNITS	N80952 001
AA	WEST WARD	50,000 USP UNITS	N80985 001
	+	50,000 USP UNITS	N80985 001

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A

AA	GLOBAL PHARM	EQ 50,000 UNITS BASE	N80953 001
AA		EQ 50,000 UNITS BASE	N80955 001
	@ IMPAX LABS	EQ 50,000 UNITS BASE	N80953 001
	@	EQ 50,000 UNITS BASE	N80955 001

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

> ADD >	AB	GENEVA PHARMS TECH	1MG	N40196 001 SEP 30, 1997
> ADD >	AB		2MG	N40196 002 SEP 30, 1997
> ADD >	AB		2.5MG	N40196 003 SEP 30, 1997
> ADD >	AB		3MG	N40196 008 JUL 26, 2000
> ADD >	AB		4MG	N40196 004 SEP 30, 1997
> ADD >	AB		5MG	N40196 005 SEP 30, 1997
> ADD >	AB		6MG	N40196 009 JUL 26, 2000
> ADD >	AB		7.5MG	N40196 006 SEP 30, 1997
> ADD >	AB		10MG	N40196 007 SEP 30, 1997
> DLT >	AB	INVAMED	1MG	N40196 001 SEP 30, 1997
> DLT >				

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

> DLT >	AB	INVAMED	2MG	N40196 002 SEP 30, 1997
> DLT >	AB		2.5MG	N40196 003 SEP 30, 1997
> DLT >	AB		4MG	N40196 004 SEP 30, 1997
> DLT >	AB		5MG	N40196 005 SEP 30, 1997
> DLT >	AB		7.5MG	N40196 006 SEP 30, 1997
> DLT >	AB		10MG	N40196 007 SEP 30, 1997

XENON, XE-133

GAS; INHALATION
XENON XE 133

AA	NYCOMED AMERSHAM	10mCi/VIAL	N17687 002
AA		20mCi/VIAL	N17687 003
		1 CI/AMP	N17256 002
@		1 CI/AMP	N17256 002
@		10mCi/VIAL	N17687 002
@		20mCi/VIAL	N17687 003

ZAFIRLUKAST

TABLET; ORAL
ACCOLATE

ASTRAZENECA	10MG	N20547 003 SEP 17, 1999

ZOLMITRIPTAN

TABLET; ORAL
ZOMIG

ASTRAZENECA	2.5MG	N20768 001 NOV 25, 1997
+	5MG	N20768 002 NOV 25, 1997
ZENECA	2.5MG	N20768 001 NOV 25, 1997

ZOLMITRIPTAN

TABLET; ORAL
ZOMIG

+ ZENECA	5MG	N20768 002 NOV 25, 1997

ZONISAMIDE

CAPSULE; ORAL
ZONEGRAN

+ DAINIPPON	100MG	N20789 001 MAR 27, 2000

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'2000 - DEC'2000

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACETAMINOPHEN

ROXANE	120MG	N71010 001 MAY 12, 1987
	650MG	N71011 001 MAY 12, 1987
@	120MG	N71010 001 MAY 12, 1987
@	650MG	N71011 001 MAY 12, 1987

TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN

PERRIGO	650MG	N75077 001 FEB 25, 2000

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
FOAMICON

GENEVA PHARMS TECH	80MG;20MG	N72687 001 JUN 28, 1989
INVAMED	80MG;20MG	N72687 001 JUN 28, 1989

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL
8-HOUR BAYER

+ BAYER	650MG	N16030 001
@	650MG	N16030 001

MEASURIN

+ BAYER	650MG	N16030 002
@	650MG	N16030 002

AVOBENZONE; PADIMATE O

LOTION; TOPICAL
PHOTOPLEX

@ ALLERGAN HERBERT	3%;7%	N19459 001 SEP 30, 1988

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
DIMETANE

@ WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983

DIMETAPP

+ WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983

CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL
PEPCID COMPLETE

+ MERCK	800MG;10MG;165MG	N20958 001 OCT 16, 2000

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL
E-Z SCRUB

BECTON DICKINSON	4%	N73416 001 MAR 14, 2000

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL
CHLORAPREP

+ MEDI FLEX HOSP	2%;70%	N20832 001 JUL 14, 2000

SPONGE; TOPICAL
CHLORAPREP

+ MEDI FLEX HOSP	2%;70%	N20832 001 JUL 14, 2000

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONTAC

@ SMITHKLINE	8MG;75MG	N18099 001
+	8MG;75MG	N18099 001

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'2000 - DEC'2000

CIMETIDINE

TABLET; ORAL
CIMETIDINE
LEINER 200MG N74961 001 JUN 19, 1998
NOVOPHARM 200MG N74961 001 JUN 19, 1998
PERRIGO 100MG N74972 001 JUN 19, 1998
@ 100MG N74972 001 JUN 19, 1998

CLOTRIMAZOLE

CREAM; VAGINAL
TRIVAGIZOLE 3
+ TARO 2% N21143 001 APR 12, 2000

DOCOSANOL

CREAM; TOPICAL
ABREVA
* AVANIR 10% N20941 001 JUL 25, 2000 > ADD >
+ SMITHKLINE BEECHAM 10% N20941 001 JUL 25, 2000 > ADD >
> ADD >

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN
PHARM FORM 200MG N74782 001 JUL 06, 1998
+ 200MG N74782 001 JUL 06, 1998

TABLET; ORAL
IBUPROFEN
LEINER 200MG N74931 001 JUL 20, 1998
NOVOPHARM 200MG N74931 001 JUL 20, 1998
MOTRIN IB
MCNEIL 200MG N19012 003 DEC 17, 1990

IBUPROFEN

TABLET; ORAL
MOTRIN MIGRAINE PAIN
+ MCNEIL 200MG N19012 004 FEB 25, 2000
NUPRIN
MCNEIL 200MG N19012 003 JUL 29, 1987
200MG N19012 002 JUL 29, 1987

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S MOTRIN COLD
+ MCNEIL CONS 100MG/5ML;15MG/5ML N21128 001 AUG 01, 2000

IBUPROFEN POTASSIUM

CAPSULE; ORAL
ADVIL MIGRAINE LIQUI-GELS
+ WHITEHALL ROBINS 200MG N20402 002 MAR 16, 2000

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
ALPHARMA 1MG/5ML N73187 001 SEP 15, 1992
@ 1MG/5ML N73187 001 SEP 15, 1992
WATSON LABS 1MG/5ML N73062 001 MAY 28, 1993
@ 1MG/5ML N73062 001 MAY 28, 1993

TABLET; ORAL
LOPERAMIDE HCL
LEINER 2MG N73254 001 JUL 30, 1993
NOVOPHARM NC 2MG N73254 001 JUL 30, 1993

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'2000 - DEC'2000

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL

PERRIGO	2MG	N75232 001 JAN 06, 2000	

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL
IMODIUM ADVANCED

MCNEIL CONS	2MG;125MG	N21140 001 NOV 30, 2000	

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)

ALPHARMA	5%	N75518 001 NOV 17, 2000	
TEVA	5%	N75619 001 NOV 17, 2000	

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
VISINE-A

~~AKORN~~	~~0.025%;0.3%~~	~~N20485 001~~ ~~JAN 31, 1996~~	~~> DLT > > DLT ><~~
PFIZER	0.025%;0.3%	N20485 001 JAN 31, 1996	> ADD > > ADD >

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997	
~~NOVOPHARM NC~~	~~EQ 200MG BASE~~	~~N74635 001~~ ~~JAN 13, 1997~~	

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

~~@ ORTHO~~	~~12.5%~~	~~N14349 002~~
@ PERSONAL PRODS	12.5%	N14349 002

PERMETHRIN

LOTION; TOPICAL
PERMETHRIN

ALPHARMA	1%	N75014 001 MAR 28, 2000

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE

+ PFIZER	4%;EQ 0.33% BASE	N21043 001 MAR 07, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

CHELSEA LABS	EQ 75MG BASE	N75212 001 JAN 14, 2000
~~CHEMINOR DRUGS~~	~~EQ 75MG BASE~~	~~N75294 001~~ ~~MAR 28, 2000~~
DR REDDYS LABS LTD	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000
LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
	EQ 75MG BASE	N75254 001 JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000
ZENITH GOLDLINE	EQ 75MG BASE	N75296 001 JAN 14, 2000

RANITIDINE HCL

~~NOVOPHARM~~	~~EQ 75MG BASE~~	~~N75094 001~~ ~~JUN 21, 1999~~

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75

* GLAXO WELLCOME	EQ 75MG BASE	N20745 001 FEB 26, 1998
@ WARNER LAMBERT	EQ 75MG BASE	N20745 001 FEB 26, 1998

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL
LAMISIL AT

+ NOVARTIS	1%	N21124 001 MAR 17, 2000

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '00

NO DECEMBER 2000 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate TN=	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 1/18/00 MA=
3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one TN=	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080 DD= 3/23/00 MA=
Abetimus TN=	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121 DD= 7/28/00 MA=
Angiotensin 1-7 TN=	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660 DD= 2/16/00 MA=
Anti-thymocyte Globulin (Rabbitt) TN=Thymoglobulin	Treatment of myelodysplastic syndrome (MDS)	SangStat Medical Corporation 6300 Dumbarton Circle Freemont CA 94555 DD= 9/6/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
arsenic trioxide TN=Atrivex	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 7/17/00 MA=
Arsenic trioxide TN=Atrivex	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite 400 Seattle WA 98119 DD= 4/28/00 MA=
Bis(4-fluorophenyl)phenylacetamide TN=	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709 DD= 3/2/00 MA=
Bosentan TN=	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd. 1840 Gateway Dr. 2nd Floor San Mateo CA 94404 DD= 10/6/00 MA=
Brimonidine TN=Alphagan	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534 DD= 2/7/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Calfactant TN=Infasurf	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park 1576 Sweet Home Road Amherst NY 14228 DD= 9/5/00 MA=
Carmustine TN=	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066 DD= 7/3/00 MA=
Centruroides immune F(ab)2 TN=Alacramyn	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de C.V. Amores #1034 Col Del Valle C.P. 03100 Mexico D.F. DD= 6/12/00 MA=
Cetuximab TN=	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876 DD= 7/3/00 MA=
Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 7/24/00 MA=
Chimeric, humanized monoclonal antibody to staphylococcus TN=	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850 DD= 8/3/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cisplatin/epinephrine TN=IntraDose	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612 DD= 4/3/00 MA=
Cisplatin/epinephrine TN=IntraDose	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612 DD= 9/7/00 MA=
Cyclosporine in combination with omega-3 polyunsaturated fatty acids TN=	Prevention of solid organ graft rejection.	RTP Pharma Corporation 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280 DD= 12/6/00 MA=
Deoxyribose, phosphorothioate TN=	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966 DD= 7/31/00 MA=
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2 TN=Leuvectin	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088 DD= 4/28/00 MA=
DNP-Modified autologous tumor vaccine TN=O-Vax	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc. 4520 Main Street Suite 930 Kansas City MO 64111 DD= 9/21/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Ethyl eicosapentaenoate TN=	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Polmaise Road, Stirling FK7 9JQ United Kingdom UK DD= 4/6/00 MA=
Flucinolone TN=	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Parkway Tampa FL 33637 DD= 7/31/00 MA=
Fluorouracil TN=	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - 92213 Saint-Cloud Cedex France FR DD= 6/29/00 MA=
Gavilimomab TN=	Acute graft-versus-host disease (aGVHD)	Abgenix, Inc. 7601 Dumbarton Circle Fremont CA 94555 DD= 11/20/00 MA=
Gene plasmid hVEGF165 driven by human cytomegalovirus, and [2,3-bis(oleoyl)propyl]trimethyl ammonium and dioleoyl phosphatidyl TN=	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Eurogene Ltd. 6 Warren Mews London W1P 5DJ UK DD= 10/24/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Meropenem TN=Merrem IV	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 DD= 4/27/00 MA=
N-acetylcysteinate TN=Nacystelyn Dry Powder	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Road 198, No. 100 km. 14.7 Juncos Industrial Park Juncos PR 00777-3873 DD= 12/27/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206 DD= 1/18/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences. Inc. 800 West 9th Avenue Amarillo TX 79101 DD= 8/10/00 MA=
Omega-3 (n-3) polyunsaturated fatty acids TN=Omacor	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway DD= 5/4/00 MA=
Phenylbutyrate TN=	Treatment of acute promyelocytic leukemia.	Elan Corporation 1300 Gould Dr. Gainesville GA 30504 DD= 1/19/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Recombinant glycine2-human glucagon-like peptide-2 TN=	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA DD= 6/29/00 MA=
Recombinant human antithrombin III TN=	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, P.O. Framingham MA 01701 DD= 4/6/00 MA=
Recombinant human highly phosphorylated acid alpha-glucosidase TN=TBD	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 9/20/00 MA=
Recombinant human insulin-like growth factor-I TN=PV802	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000 Australia AU DD= 2/16/00 MA=
Recombinant urate oxidase TN=	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355 DD= 10/11/00 MA=
Recombinant urate oxidase TN=	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355 DD= 10/11/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Remacemide TN=Ecovia	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 3/6/00 MA=
rSP-C lung surfactant TN=Venticute	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 78467 Konstanz Germany DE DD= 4/3/00 MA=
SB-408075 TN=	For pancreatic cancer	SmithKline Beecham Pharmaceuticals 1250 S. Collegeville Road Collegeville PA 19426-0989 DD= 12/7/00 MA=
Soluble complement receptor type 1 TN=	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc. 119 Fourth Ave. Needham MA 02494-2725 DD= 3/6/00 MA=
somatropin [rDNA] TN=Genotropin	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company 7000 Portage Road Kalamazoo MI 49001 DD= 12/27/00 MA=
Synthetic human secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Synthetic porcine secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=
Technetium Tc 99m pterotetramide TN=	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906 DD= 2/16/00 MA=
Technetium Tc99m rh-Annexin V TN=Apomate	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation 124 Mount Auburn Street Suite 200 North Cambridge MA 02138 DD= 11/3/00 MA=
Tetraiodothyroacetic acid TN=	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489 DD= 5/1/00 MA=
Thymalfasin TN=Zadaxin	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc. 901 Mariner's Blvd., Suite 205 San Mateo CA 94404 DD= 3/6/00 MA=
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide) TN=	Chronic myelogenous leukemia (CML)	ICN Pharmaceuticals, Inc. (ICN) 3300 Hyland Avenue Costa Mesa CA 92626 DD= 12/27/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Trimetrexate TN=Neutrexin	Treatment of metastatic osteogenic sarcoma.	Medimmune Oncology, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken PA 19428 DD= 8/10/00 MA=
Vapreotide TN=Octastatin	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
Vapreotide TN=Octastatin	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 3/6/00 MA=
Vapreotide TN=Octastatin	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
vigabatrin TN=Sabril	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627 Kansas City MO 64137 DD= 6/12/00 MA=

Orphan Products Designations and Approvals List
January through December 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Zoledronate TN=Zometa, Zabel	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936-1080 DD= 8/18/00 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 2000 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394*PED	DEC 26, 2009		NCE	NOV 17, 2000
>ADD>			5047407*PED	MAY 17, 2010		NCE	DEC 17, 2003
>ADD>			5905082*PED	NOV 18, 2016		PED	MAY 17, 2001
>ADD>			5089500*PED	DEC 26, 2009	U-248	PED	JUN 17, 2004
			5034394	JUN 26, 2009			
			5089500	JUN 26, 2009	U-248		
			5047407	NOV 17, 2009			
			5905082	MAY 18, 2016			
			4724232	SEP 17, 2005			
			4818538	SEP 17, 2005			
			4833130	SEP 17, 2005			
			4837208	SEP 17, 2005			
			4828838	SEP 17, 2005			
	075077 001	ACETAMINOPHEN;ACETAMINOPHEN				PC	NOV 12, 2000
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
	020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
			RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012		I-309	SEP 29, 2003
	020560 002	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
	020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
			6090410	DEC 02, 2012			
>ADD>	020560 004	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012		NS	OCT 20, 2003
>ADD>			5994329	JUL 17, 2018		D-61	OCT 20, 2003
			6015801	JUL 17, 2018	U-353	D-62	OCT 20, 2003
			4621077	AUG 06, 2007	U-114		
			5358941	DEC 02, 2012			
			5681590	DEC 02, 2012			
			5804570	FEB 17, 2015			
			5849726	JUN 06, 2015			
			6008207	JUN 06, 2015			
>ADD>	020560 005	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012		NS	OCT 20, 2003
			6015801	JUL 17, 2018	U-353	D-61	OCT 20, 2003
			4621077	AUG 06, 2007	U-114	D-62	OCT 20, 2003
			5358941	DEC 02, 2012			
			5681590	DEC 02, 2012			
			5804570	FEB 17, 2015			
			5849726	JUN 06, 2015			
			5994329	JUL 17, 2018			
			6008207	JUN 06, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
	018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	018276 004	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
	020221 001	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	020221 002	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
>ADD>	020364 002	AMLODIPINE BESYLATE;LOTREL	6162802	DEC 19, 2017	U-367		
>ADD>	020364 003	AMLODIPINE BESYLATE;LOTREL	6162802	DEC 19, 2017	U-367		
>ADD>	020364 004	AMLODIPINE BESYLATE;LOTREL	6162802	DEC 19, 2017	U-367		
	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4	AUG 25, 2003
>ADD>						PED	FEB 25, 2004
	021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021039 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
	020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
	020883 001	ARGATROBAN;ACOVA				NCE	JUN 30, 2005
	021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
						NCE	SEP 25, 2005
	020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR	6126971	JAN 19, 2013			
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	6126971	JAN 19, 2013			
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR	6126971	JAN 19, 2013			
>ADD>	020702 004	ATORVASTATIN CALCIUM;LIPITOR	6126971	JAN 19, 2013		NCE	DEC 17, 2001
			4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
			5273995	DEC 28, 2010	U-162	I-218	JUL 10, 2001
			5686104	NOV 11, 2014	U-213	I-219	JUL 10, 2001
			5969166	JUL 08, 2016			
>ADD>	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013			
>ADD>	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013			
	021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
			5164194*	MAY 01, 2011		NDF	MAY 22, 2003
						PED	MAY 01, 2002
						PED	NOV 22, 2003
	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2001		NCE	JUL 18, 2005
	020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015			
			5605674	FEB 25, 2014			
			5695743	JUL 06, 2010			
			5683677	NOV 04, 2014			
			5766573	NOV 28, 2009	U-356		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	5776432	JUL 07, 2015			
			5605674	FEB 25, 2014			
			5695743	JUL 06, 2010			
			5683677	NOV 04, 2014			
			5766573	NOV 28, 2009	U-356		
	020010 001	BETAMETHASONE DIPROPIONATE;LOTRISONE				NP	DEC 08, 2003
	021055 001	BEXAROTENE;TARGRETIN				ODE	DEC 29, 2006
	021056 001	BEXAROTENE;TARGRETIN				NCE	DEC 29, 2004
						NDF	JUN 28, 2003
	019982 001	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	019982 002	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 001	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 002	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 003	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4358062*PED	SEP 24, 2000	U-63		
>ADD>	020873 001	BIVALIRUDIN;ANGIOMAX				NCE	DEC 15, 2005
	050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
	020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
>ADD>	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	6150365*PED	FEB 05, 2020	U-361		
			4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
			6150365	AUG 05, 2019	U-361		
>ADD>	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	6150365*PED	FEB 05, 2020			
			4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
			6150365	AUG 05, 2019	U-361		
>ADD>	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	6150365*PED	FEB 05, 2020			
			5015646	MAY 14, 2008			
			4182763	MAY 22, 2000	U-13		
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
			6150365	AUG 05, 2019	U-361		
>ADD>	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	6150365*PED	FEB 05, 2020			
			4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000			
			5015646*PED	NOV 14, 2008	U-13		
			6150365	AUG 05, 2019			
					U-361		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
>ADD>			5015646*PED	NOV 14, 2008			
>ADD>	021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
>ADD>			5015646	MAY 14, 2008			
>ADD>	021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
>ADD>			5015646*PED	NOV 14, 2008			
>ADD>	021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
>ADD>			5015646*PED	NOV 14, 2008			
	020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	MAR 31, 2015			
	018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
	018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
	020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U-349	NC	OCT 15, 2003
			4283408	OCT 15, 2000		PED	APR 15, 2004
			5817340	DEC 01, 2012			
			5989588	SEP 30, 2015	U-349		
			5989588*PED	MAR 30, 2018	U-349		
			4283408*PED	APR 15, 2001			
			5229137*PED	NOV 16, 2012			
			5817340*PED	JUN 01, 2013			
	021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
			5958961	JUN 06, 2014	U-3		
			5196444	APR 18, 2011	U-3		
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011	U-3		
	021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
			5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
			5958961	JUN 06, 2014	U-3		
			5196444	APR 18, 2011	U-3		
			5534534	JUL 09, 2013			
			5703110	APR 18, 2011	U-3		
	020896 001	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020896 002	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020297 001	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 002	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 003	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 004	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020740 001	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 002	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 003	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020740 004	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 005	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
			5177080	JAN 26, 2011		I-303	JUL 21, 2003
						NS	JUL 21, 2003
	021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
			5198533	JUL 17, 2007			
	021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
			5198533	JUL 17, 2007			
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
			5340821	AUG 23, 2011	U-309		
			5580880	JUN 06, 2015	U-310		
	020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
	021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	020780 001	CIPROFLOXACIN;CIPRO	6136347	JAN 06, 2013	U-362		
	020780 002	CIPROFLOXACIN;CIPRO	6136347	JAN 06, 2013	U-362		
	020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
	021143 001	CLOTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
			5679717	APR 29, 2014	U-323		
			5693675	DEC 02, 2014			
			5607669	JUN 10, 2014	U-323		
			5917007	APR 29, 2014	U-323		
			5919832	JUN 10, 2014			
	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
			5917007	APR 29, 2014	U-323		
			5607669	JUN 10, 2014	U-323		
			5693675	DEC 02, 2014			
			5679717	APR 29, 2014	U-323		
			5624963	APR 29, 2014	U-323		
	020287 001	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
	020287 003	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
	020287 004	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
>ADD>	021090 001	DESOGESTREL;CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
>ADD>			4544554	SEP 26, 2003			
>ADD>			4628051	SEP 26, 2003			
	020713 001	DESOGESTREL;MIRCETTE	RE35724	OCT 20, 2008			
	020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
			4963551	DEC 21, 2007			
			4275063	JUN 23, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
			4963551	DEC 21, 2007			
			4275063	JUN 23, 2003			
	020154 002	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 003	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180	D-58	OCT 28, 2002
	020154 005	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
						D-58	OCT 28, 2002
	021183 001	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
	021183 002	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
	021183 003	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
	021183 004	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
	020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
>ADD>	020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
>ADD>	020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
>ADD>	020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
>ADD>	020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
>ADD>	020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
>ADD>	020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	6162463	APR 28, 2018			
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
			4913906	APR 03, 2007			
	020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
	020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			
	020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			
	020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018			
>ADD>	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011			
			4906775	JUL 02, 2011			
>ADD>	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011			
			4906775	JUL 02, 2011			
>ADD>	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011			
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	JUN 07, 2014			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	JUN 07, 2014			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
			4619939	OCT 28, 2003	U-104		
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
			5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4413141	NOV 01, 2000		NP	JUL 27, 2003
		4720489	JAN 19, 2005	U-334		
		5648394	JUL 15, 2014	U-334		
019221 001	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
		4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
		4472380*PED	MAR 18, 2002			
019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
		4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
		4472380*PED	MAR 18, 2002			
018998 001	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
018998 002	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
018998 003	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
018998 005	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
019309 001	ENALAPRILAT;VASOTEC	4374829	FEB 22, 2000			
		4374829*PED	AUG 22, 2000			
020164 001	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
020164 002	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
020164 003	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
020164 004	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
020164 005	ENOXAPARIN SODIUM;LOVENOX				I-315	NOV 17, 2003
020444 001	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
					I-296	APR 14, 2003
020444 002	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
					I-296	APR 14, 2003
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLE	RE36247	MAY 02, 2006		I-295	APR 11, 2003
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011			
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
			5382573	JAN 17, 2012			
	020323 001	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 002	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 003	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 004	ESTRADIOL;VIVELLE				I-254	AUG 16, 2003
	020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
			5300291	APR 05, 2011		I-254	AUG 16, 2003
			4814168	MAR 04, 2008			
			4994267	MAR 04, 2008			
>ADD>	020538 001	ESTRADIOL;VIVELLE-DOT	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
>ADD>	020538 002	ESTRADIOL;VIVELLE-DOT	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
>ADD>	020538 003	ESTRADIOL;VIVELLE-DOT	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
>ADD>	020538 004	ESTRADIOL;VIVELLE-DOT	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
>ADD>	020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		NP	MAR 24, 2002
>ADD>	020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CY	RE36247	MAY 02, 2006	U-284		
>ADD>	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006	U-284		
>ADD>	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006	U-284		
>ADD>	075665 001	ETODOLAC;ETODOLAC				PC	FEB 13, 2001
>ADD>	075665 002	ETODOLAC;ETODOLAC				PC	FEB 13, 2001
	075696 001	ETODOLAC;ETODOLAC				PC	FEB 04, 2001
	020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	019462 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	019462 002	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019510 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	019527 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	020325 001	FAMOTIDINE;PEPCID AC	4283408	OCT 15, 2000		D-47	NOV 09, 2001
			5667794	MAY 02, 2015	U-205	PED	MAY 09, 2002
			5854267	DEC 29, 2015	U-267		
			4283408*PED	APR 15, 2001			
			5667794*PED	NOV 02, 2015	U-205		
			5854267*PED	JUN 29, 2016	U-267		
	020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
			4283408	OCT 15, 2000			
			5854267	DEC 29, 2015	U-267		
			5075114	DEC 24, 2008			
			4283408*PED	APR 15, 2001			
			5075114*PED	JUN 24, 2009			
			5667794*PED	NOV 02, 2015			
			5854267*PED	JUN 29, 2016			
>ADD>	020902 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-368		
>ADD>			5854267*PED	JUN 29, 2016	U-368		
>ADD>			5667794	MAY 02, 2015	U-368		
>ADD>			5667794*PED	NOV 02, 2015	U-368		
>ADD>			4820524*PED	AUG 20, 2007			
>ADD>			4820524	FEB 20, 2007			
			4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	019510 004	FAMOTIDINE;PEPCID PRESERVATIVE	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	020249 001	FAMOTIDINE;PEPCID PRESERVATIVE	4283408	OCT 15, 2000			
			4238408*PED	APR 15, 2001			
	020752 001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	020752 002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
			4283408*PED	APR 15, 2001			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015		NCE	JUL 25, 2001
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
			6113942	FEB 28, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
019949 004	FLUCONAZOLE;DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
020985 001	FLUOROURACIL;FLUOROURACIL				NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-154		
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-154		
		4626549*PED	JUN 02, 2004	U-84		
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JUN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JAN 06, 2004
		5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
021192 001	FLUVASTATIN SODIUM;LESCOL XL				NDF	OCT 06, 2003
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
					I-306	MAY 24, 2003
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
					I-306	MAY 24, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
			5767251	JUN 16, 2015		ODE	MAY 24, 2007
>ADD>	020696 001	FOMEPIZOLE;ANTIZOL				ODE	DEC 08, 2007
>ADD>						I-319	DEC 08, 2003
	020235 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476	MAY 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4087544	JAN 16, 2000	U-86	I-311	OCT 12, 2003
			5084479*PED	JUL 02, 2010	U-125		
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476	MAY 02, 2008		I-311	OCT 12, 2003
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010			
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106	I-311	OCT 12, 2003
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			5084479*PED	JUL 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106	I-311	OCT 12, 2003
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			5084479*PED	JUL 02, 2010	U-258		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021129 001	GABAPENTIN;NEURONTIN				I-311	OCT 12, 2003
	021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
			5560903	OCT 01, 2013			
			4647447	MAR 03, 2004			
			4957939	MAR 03, 2004			
			4963344	MAR 03, 2004			
	020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
			4423050	MAY 21, 2001	U-64		
			4355032	JUN 23, 2003	U-64		
			4642346	JUN 24, 2005			
	021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
			5693762	DEC 02, 2014		NCE	MAY 17, 2005
			5739116	APR 14, 2015			
			5767285	JUN 16, 2015			
			5773001	JUN 30, 2015	U-320		
			4970198	NOV 30, 2007			
			5079233	JAN 07, 2009			
			5585089	DEC 17, 2013			
	020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014			
			6054430	MAY 24, 2014			
	021178 001	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	021178 002	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	021178 003	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
	021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
	021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
>ADD>	019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
>ADD>	019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
>ADD>	019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
	019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
			4552899*PED	OCT 09, 2004			
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO				NP	AUG 01, 2003
>ADD>	019012 004	IBUPROFEN;MOTRIN MIGRAINE PAIN				NP	FEB 26, 2003
>ADD>	020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009			
	019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
			5696172	OCT 06, 2013			
	019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
			5696172	OCT 06, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020986 001	INSULIN ASPART RECOMBINANT;NOVOLOG				NCE	JUN 07, 2005
021081 001	INSULIN GLARGINE;LANTUS				PED	OCT 20, 2005
					NCE	APR 20, 2005
020563 001	INSULIN LISPRO;HUMALOG				D-56	APR 04, 2003
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50				NC	DEC 22, 2002
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014			
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR				I-299	APR 20, 2003
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005			
019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
020857 001	LAMIVUDINE;COMBIVIR	4828838*PED	MAR 17, 2006		NCE	NOV 17, 2000
		4833130*PED	MAR 17, 2006		PED	MAY 17, 2001
		4837208	SEP 17, 2005			
		5047407*PED	AUG 08, 2009			
		4724232*PED	MAR 17, 2006			
		4818538*PED	MAR 17, 2006			
		5859021*PED	NOV 15, 2012	U-248		
		5905082*PED	NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*PED	APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*PED	MAR 17, 2006			
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		5905082	MAY 18, 2016		PED	MAY 17, 2001
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		6004968	MAR 20, 2018		PED	MAY 17, 2001
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
		5532246	JUL 02, 2013	U-250	PED	JUN 08, 2002
		5905082	MAY 18, 2016			
		5047407*PED	AUG 08, 2009			
		5532246*PED	JAN 02, 2014	U-250		
		5905082*PED	NOV 18, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		NCE	NOV 17, 2000
			5532246	JUL 02, 2013	U-250	I-257	DEC 08, 2001
			6004968	MAR 20, 2018		PED	MAY 17, 2001
			5047407*PED	AUG 08, 2009		PED	JUN 08, 2002
			5532246*PED	JAN 02, 2014	U-250		
			6004968*PED	SEP 20, 2018			
	020406 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
	020406 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
>ADD>	020726 001	LETROZOLE;FEMARA				I-318	JAN 10, 2004
>ADD>	021088 001	LEUPROLIDE ACETATE;VIADUR	6156331	JAN 30, 2017		NP	MAR 03, 2003
			5728396	JAN 30, 2017	U-316		
			5932547	JUN 13, 2017			
			5985305	JAN 30, 2017			
			6113938	JUL 24, 2018			
			6124261	JUN 13, 2017			
			6132420	JAN 30, 2017			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
>ADD>	021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4911920	MAR 27, 2007	U-369	NP	FEB 23, 2003
>ADD>			5540918	JUL 30, 2013			
>ADD>	020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
>ADD>	020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
>ADD>	020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010			
>ADD>	020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-305	FEB 02, 2003
>ADD>	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE	5053407	DEC 20, 2010		I-305	FEB 02, 2003
>ADD>	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE	5053407	DEC 20, 2010		I-305	FEB 02, 2003
	021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
			5503407	OCT 01, 2008			
			4551456	NOV 14, 2003			
			5053407	OCT 01, 2008			
	021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
	019941 001	LIDOCAINE;EMLA				I-314	JAN 28, 2003
	020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
>ADD>	019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD>	021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5612054	SEP 28, 2010			
>ADD>			5248505	SEP 28, 2010			
	021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U-351	NC	SEP 15, 2003
			5635523	JUN 30, 2014	U-352	NCE	MAR 01, 2001
			5541206	JUL 30, 2013	U-348		
			5674882	OCT 07, 2014	U-344		
			5886036	DEC 29, 2012	U-345		
			6037157	JUN 26, 2016	U-346		
			5846987	DEC 29, 2012	U-350		
			5648497	JUL 15, 2014			
	021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U-348	NC	SEP 15, 2003
			5914332	DEC 13, 2005	U-351	NCE	MAR 01, 2001
			5635523	JUN 03, 2014	U-352		
			5846987	DEC 29, 2012	U-350		
			5648497	JUL 15, 2014			
			5674882	OCT 07, 2014	U-344		
			5886036	DEC 29, 2012	U-345		
			6037157	JUN 26, 2016	U-346		
	019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
	020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
			4282233*PED	DEC 19, 2002	U-77		
			6132758	JUN 01, 2018			
	020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			4371516	FEB 01, 2000			
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4282233*PED	DEC 19, 2002	U-77		
			4371516*PED	AUG 01, 2000			
			4863931*PED	MAR 15, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019670 001	LORATADINE;CLARITIN-D	4282233	JUN 19, 2002	U-77		
			4659716	APR 21, 2004	U-142		
			4863931	SEP 15, 2008			
			4282233*PED	DEC 19, 2002	U-77		
			4659716*PED	OCT 21, 2004	U-142		
			4863931*PED	MAR 15, 2009			
	020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
			4282233	JUN 19, 2002	U-77		
			5314697*PED	APR 23, 2013			
			4863931	SEP 15, 2008			
			4659716*PED	OCT 21, 2004	U-142		
			4282233*PED	DEC 19, 2002	U-77		
			4863931*PED	MAR 15, 2009			
			5314697	APR 23, 2013			
>ADD>	020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012			
>ADD>	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012			
	020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
	020049 001	MESALAMINE;PENTASA	4980173	JAN 29, 2002	U-78		
	019884 001	MESNA;MESNEX	5696172	OCT 06, 2013			
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	APR 22, 2002
>ADD>						PED	JUN 15, 2004
>ADD>						I-320	DEC 15, 2003
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	APR 22, 2002
>ADD>						PED	JUN 15, 2004
>ADD>						I-320	DEC 15, 2003
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	SEP 03, 2000
						PED	APR 22, 2002
>ADD>						PED	JUN 15, 2004
>ADD>						I-320	DEC 15, 2003
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	SEP 03, 2000
						PED	APR 22, 2002
>ADD>						PED	JUN 15, 2004
>ADD>						I-320	DEC 15, 2003
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	SEP 03, 2000
						NCE	MAR 03, 2000
						I-307	OCT 22, 2001
						PED	APR 22, 2002
>ADD>						PED	JUN 15, 2004
>ADD>						I-320	DEC 15, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR				NDF	OCT 13, 2003
>ADD>	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
>ADD>			4783337	SEP 16, 2003			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
>ADD>			4783337	SEP 16, 2003			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003			
>ADD>			4783337	SEP 16, 2003			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
	019532 001	METOLAZONE;MYKROX	4517179	APR 29, 2003			
>ADD>	020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5840744	JAN 15, 2008	U-370		
	019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
	019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
	020687 001	MIFEPRISTONE;MIFEPREX	4386085	JAN 08, 2002		NCE	SEP 28, 2005
			4447424	JAN 08, 2002			
			4626531	OCT 12, 2004			
>ADD>	020415 001	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
>ADD>	020415 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
>ADD>	020415 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
>ADD>	021208 001	MIRTAZAPINE;REMERON	5977099	JUN 26, 2017			
>ADD>	021208 002	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
>ADD>	021208 003	MIRTAZAPINE;REMERON	5977099	JUN 16, 2017			
	021120 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6127353	OCT 03, 2017			
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	I-300	MAR 03, 2003
						NS	MAR 03, 2003
						NCE	FEB 20, 2003
	019516 001	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 002	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 003	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 004	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
	019516 005	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
>ADD>	021204 001	NATEGLINIDE;STARLIX				NCE	DEC 22, 2005
>ADD>	021204 002	NATEGLINIDE;STARLIX				NCE	DEC 22, 2005
	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 005	NIACIN;NIASPAN TITRATION ST	6080428	MAY 27, 2017	U-331		
020076 001	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 002	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 003	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	6098632	JUN 08, 2010			
021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003			
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 002	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 003	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 004	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 005	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020592 006	OLANZAPINE;ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL				I-301	MAR 20, 2003
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4695578	JAN 25, 2005	U-183		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-329		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
			6063802	NOV 14, 2015			
			5578628	JUN 24, 2006	U-330		
			4695578	JAN 25, 2005	U-330		
			4753789	JUN 24, 2006	U-330		
	020766 001	ORLISTAT;XENICAL	6004996	JAN 06, 2018			
>ADD>	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU				I-317	NOV 17, 2003
	021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	075184 001	PACLITAXEL;PACLITAXEL				PC	APR 21, 2001
	020262 001	PACLITAXEL;TAXOL	6096331	FEB 22, 2013		D-57	JUN 20, 2003
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
	020819 001	PARICALCITOL;ZEMPLAR	5246925	SEP 21, 2010	U-314		
			5587497	DEC 24, 2013			
			6136799	APR 08, 2018			
>ADD>	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6113944	DEC 14, 2014			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6113944	DEC 14, 2014			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6113944	DEC 14, 2014			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6113944	DEC 14, 2014			
			6133289	MAY 15, 2015	U-358		
>ADD>	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6113944	DEC 14, 2014			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 15, 2015	U-358		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6172233	JAN 15, 2018			
			6062927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-358		
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6172233	JAN 15, 2018			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR				NDF	FEB 16, 2002
	021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCT	5607979	MAY 30, 2015		NCE	FEB 17, 2005
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	6048901	APR 20, 2019	U-343		
	019898 002	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
	019898 003	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019898 004	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
						I-304	JAN 18, 2003
						I-287	FEB 10, 2003
						I-286	JAN 18, 2003
						D-51	JAN 18, 2003
>ADD>	075117 001	PREDNISOLONE SODIUM PHOSPHATE;ORAPRED				PC	JUL 02, 2001
	019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
	019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
			5061722	OCT 19, 2008	U-3		
	019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
			5061722	OCT 19, 2008	U-3		
	019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
			5061722	OCT 19, 2008	U-3		
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008	U-3	I-310	OCT 04, 2003
			4587258	JAN 27, 2005			
	020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583	FEB 15, 2009		PED	JAN 12, 2002
			5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
	020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
			5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
	020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
			5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
			5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
			5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
	020903 001	RIBAVIRIN;REBETOL	6051252	DEC 22, 2017			
>ADD>	020835 001	RISEDRONATE SODIUM;ACTONEL	6096342	MAR 12, 2017		I-292	APR 14, 2003
>ADD>			6165513	JUN 10, 2018		I-291	APR 14, 2003
						I-290	APR 14, 2003
						I-293	APR 14, 2003
>ADD>	020835 002	RISEDRONATE SODIUM;ACTONEL	6096342	MAR 12, 2017		I-292	APR 14, 2003
>ADD>			6165513	JUN 10, 2018		NCE	MAR 27, 2003
			5583122	DEC 10, 2013	U-222	I-291	APR 14, 2003
						I-293	APR 14, 2003
						I-290	APR 14, 2003
	020588 001	RISPERIDONE;RISPERDAL	5453425	JUL 11, 2014			
			5616587	JUL 11, 2014			
	020659 001	RITONAVIR;NORVIR	6037157	JUN 26, 2016			
			5674882	OCT 07, 2014			
			5886036	DEC 29, 2012			
	020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014		NCE	MAR 01, 2001
			5846987	DEC 29, 2012	U-347		
			5541206	JUL 30, 2013	U-348		
			5635523	JUN 03, 2014	U-347		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	021042 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021042 003	ROFECOXIB;VIOXX				NCE	MAY 20, 2004
	021052 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
	020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
	020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
	020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
>ADD>	020236 001	SALMETEROL XINAFOATE;SEREVENT				M-5	JUN 30, 2003
>ADD>	020692 001	SALMETEROL XINAFOATE;SEREVENT				M-5	JUN 30, 2003
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
			4940731	AUG 30, 2009	U-312		
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		NCE	JUN 07, 2000
			6074668	JAN 09, 2018		PED	DEC 07, 2000
			5990176*PED	JUL 27, 2017			
			6074668*PED	JUL 09, 2018			
	021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	APR 01, 2017	U-359	NP	SEP 21, 2003
	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
						ODE	JUN 20, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-302	JUN 20, 2000
					ODE	JUN 20, 2007
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5716338	FEB 10, 2015		I-302	JUN 20, 2003
		5435076	APR 16, 2013		ODE	JUN 20, 2007
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
		5716338	FEB 10, 2015		ODE	JUN 20, 2007
019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
					M-2	DEC 01, 2002
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
					M-2	DEC 01, 2002
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340		
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
021184 001	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
021184 002	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
					NDF	SEP 29, 2003
020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5431900	JUL 11, 2012	U-336		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
			4894445	JAN 16, 2007	U-337		
			5324824	JAN 16, 2007			
			4885100	SEP 11, 2007			
			4988827	JAN 29, 2008			
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
			4755534	DEC 30, 2006	U-73		
			5681849	OCT 28, 2014			
	021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
>ADD>	020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U-371		
>ADD>	020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
>ADD>	020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
	020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
>ADD>	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	6136794	JAN 29, 2019			
>ADD>	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	6136794	JAN 29, 2019			
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
>ADD>	021228 001	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
>ADD>						NCE	MAR 25, 2003
>ADD>	021228 002	TOLTERODINE TARTRATE;DETROL LA	5382600	JAN 17, 2012		NDF	DEC 22, 2003
>ADD>						NCE	MAR 25, 2003
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	SEP 03, 2000
						PED	FEB 21, 2002
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
						D-63	DEC 23, 2002
>ADD>						PED	JUN 23, 2003
	021108 001	TRETINOIN;RENOVA				NP	AUG 31, 2003
	074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
			5962461	AUG 07, 2016			
	020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010		NCE	JUN 15, 2005
			5225205	JUL 20, 2010			
			5192741	MAR 09, 2010			
	020719 001	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 002	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 003	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020720 001	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 002	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020720 003	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		
	021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
			5151444	MAR 19, 2008	U-333		
			5166178	NOV 24, 2009	U-333		
			5212200	MAY 18, 2010	U-333		
			5208256	MAY 21, 2011	U-333		
			5221763	JUN 22, 2010			
>ADD>	020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
>ADD>			4567182	JAN 28, 2003			
>ADD>			5879706	JAN 19, 2016			
>ADD>			6107302	JAN 19, 2016			
>ADD>	020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4567182	JAN 28, 2003			
>ADD>			5879706	JAN 19, 2016			
>ADD>			6107302	JAN 19, 2016			
>ADD>			4957924	JUN 23, 2009			
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
			6096339	APR 04, 2017	U-365		
			6146662	NOV 14, 2017	U-366		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
			6096339	APR 04, 2017	U-365		
			6146662	NOV 14, 2017	U-366		
	021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
			6074666	FEB 05, 2012			
			4920143	APR 24, 2007			
			5095030	APR 24, 2007			
			5214036	MAY 25, 2010			
			5770619	JAN 06, 2015	U-357		
			5798349	AUG 25, 2015	U-357		
			5756541	MAR 11, 2016	U-357		
	020547 001	ZAFIRLUKAST;ACCOLATE	5583152	SEP 26, 2010			
			6143775	DEC 11, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		NCE	SEP 26, 2001
		5294636	DEC 11, 2011		I-268	SEP 17, 2002
		5319097	DEC 11, 2011		NS	SEP 17, 2002
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
		6143775	DEC 11, 2011			
021036 001	ZANAMIVIR;RELENZA				I-294	APR 26, 2003
020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 20TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NPP	NEW PATIENT POPULATION

REFERENCES

NEW DOSING SCHEDULE

D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML

NEW INDICATION

I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

MISCELLANEOUS EXCLUSIVITY CODES

M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION

PATENT USE CODE

U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT- LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA,. PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATER OF THIS SNDA-011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

*U.S. Government Printing Office: 2001— 472-432/21006

New 21st Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐–☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( )
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/00)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.